US Pat. No. 10,455,942

FOLDING CHAIR AND FOLDING SUPPORT THEREOF

Libin Chen, Changzhou (C...

1. A folding support, comprising:a linkage mechanism, the linkage mechanism comprising two linkage rods which cross each other and are hinged;
two support mechanisms, which are disposed in a mirror image relationship on two sides of said linkage mechanism respectively, each support mechanism comprising an upright rod, a sliding sleeve, a connector, and two diagonal bracing mechanisms;
said sliding sleeves being slidably received on said upright rods, an upper end of one linkage rod being hinged with said sliding sleeve, and a lower end of the other linkage rod being hinged with a lower end of said upright rod;
said two diagonal bracing mechanisms being disposed in a mirror image relationship with respect to said upright rods, each said diagonal bracing mechanism comprising a diagonal bracing rod and a bottom frame rod, an upper end of said diagonal bracing rod being hinged with said sliding sleeve, and a lower end of said diagonal bracing rod being hinged with one end of said bottom frame rod, an opposite end of said bottom frame rod being hinged with said connector, and a lower end of one linkage rod is hinged with said connector.

US Pat. No. 10,455,941

COLLAPSIBLE BUTTERFLY CHAIR

ZHEJIANG SUNSHINE LEISURE...

1. A collapsible butterfly chair, comprising a support frame and a chair cover, characterized in that the support frame comprises two first long side support rods, two second short side support rods, two front crossed rods hinged together in a crossed mode, two rear crossed rods hinged together in a crossed mode, and two support rods; the first side support rods and the second side support rods are hinged together in a crossed mode and separately arranged on two opposite side vertical faces, lower ends of the two front crossed rods are separately hinged to lower ends of the two first side support rods, upper ends of the two front crossed rods are separately hinged to upper ends of the two second side support rods, lower ends of the two rear crossed rods are separately hinged to lower ends of the two second side support rods, and upper ends of the two rear crossed rods are separately hinged to the two first side support rods; and the collapsible butterfly chair further comprises two sliding sleeves which are slidably arranged on the two first side support rods in a sleeving mode separately, lower ends of the support rods are hinged to the sliding sleeves, and upper ends of the support rods are hinged to the upper ends of the second side support rods.

US Pat. No. 10,455,939

ONE PIECE INJECTION-MOLDED STACKABLE ROCKING CHAIR

1. A stackable rocking chair comprising:a seat, a back, a pair of front legs, and a pair of rear legs, said front and rear legs splayed downwardly and outwardly from said seat so as to form a downwardly and outwardly diverging cavity below said seat that permits a second substantially similar rocking chair to be nested largely within said cavity;
a pair of rockers extending between said pair of front and rear legs, respectively, each of said rockers being downwardly curved and having an inner sidewall and an outer sidewall;
a curved bottom wall integral with and connecting said inner and outer sidewalls, a portion of said curved bottom wall touching the ground as the rocking chair rocks back and forth, said curved bottom wall including a plurality of drain holes;
said pair of rockers each having a plurality of substantially planar thin-wall ribs extending between said inner and outer sidewalls, said thin-wall ribs forming an acute angle with said inner and outer sidewalls, resulting in a plurality of polygonal cells;
said rockers having an open top between the inner and outer sidewalls such that said thin-wall ribs are substantially exposed at the top thereof;
wherein said seat, back, front legs, rear legs, rockers, inner and outer sidewalls, bottom wall, and thin-wall ribs are injection-molded in one piece; and
wherein each of said thin-wall ribs are oriented at the same angle with respect to one another, and at a different angle with respect to said curved bottom wall, so as to permit a mold to be removed therefrom in an upward motion.

US Pat. No. 10,455,936

METHOD AND APPARATUS FOR DISPENSING SANITIZER FLUID, OPENING DOORS, AND RECORDING DATA PERTAINING TO HAND SANITIZATION

Altitude Medical, Inc., ...

1. A hand sanitization device comprising:a housing configured to be mounted on a door comprising a handle, wherein the housing comprises an upper housing portion, a lower housing portion, and a narrow housing portion therebetween, wherein the handle comprises a rose, and wherein the housing is configured to be mounted on the door such that the upper housing portion lies above the rose, the lower housing portion lies below the rose, and the narrow housing portion lies adjacent the rose and conforms thereto;
a cartridge disposed within the housing, wherein the cartridge contains a sanitizer agent;
an actuatable pump disposed in the housing and operably coupled with the cartridge, wherein actuation of the actuatable pump causes the cartridge to dispense the sanitizer agent to a user's hand;
an actuation mechanism operably coupled to the actuatable pump and movable from a first position to a second position, wherein movement of the actuation mechanism from the first position to the second position by the user's hand actuates the pump; and
a pump sheath adjacent the pump and coupled to the cartridge, the pump sheath acting to protect internal components in the housing from being splashed by the sanitizer agent when dispensed from the pump.

US Pat. No. 10,455,928

HAIR BRUSH ELEMENT AND HAIR BRUSH CONFIGURATIONS

1. A hair brush element configuration comprising:a base;
bristles secured to the base; and
a plurality of brush elements secured to the base, the brush elements each including
a pedestal having a first end and a second end;
a setting fixed to the second end of the pedestal, wherein the setting includes
a plurality of first elements extending from the setting, wherein the first elements extend out from the setting, and wherein the setting is a spherical element having an increased width relative to the pedestal element, and
a plurality of second elements extending from the setting, wherein the second elements extend out from the setting and are interspersed with the first elements on the setting, and wherein the second elements have a smaller width relative to the first elements.

US Pat. No. 10,455,927

LOOP FOR USE WITH A VARIETY OF HANDHELD DEVICE CASES

GENEZE INNOVATION INC., ...

1. A loop apparatus for secure manipulation of a protective case for a handheld device, the protective case including at least one existing opening corresponding to existing features of the handheld device including at least one of an existing main opening for receiving the handheld device, an existing data port opening, an existing speaker opening, an existing camera opening, or an existing other opening, the handheld device having a front side and a back side, the protective case having an inside and an outside, the apparatus comprising:a strap having a flat shape of predetermined thickness, width and length thereby delimiting a front side of the strap, a backside of the strap, two ends of the strap, and a middle portion of the strap between the two ends;
a manipulative portion of the loop provided in the middle portion of the strap on the outside of the protective case to facilitate manipulation, the manipulative portion further including at least one fold provided in the middle portion of the strap, the at least one fold configured such that each of the two ends of the strap is passable through the at least one existing opening in the protective case so as to reach the inside of the protective case; and
an operative portion of the loop provided in at least one of the two ends of the strap on the inside of the protective case to secure the loop, the operative portion including at least one adhesive layer provided on the at least one of the two ends of the strap, the at least one adhesive layer adherable onto at least one of the inside of the protective case, the back of the handheld device, the front side of the strap, or the backside of the strap;wherein the operative portion of the loop is squeezed between the inside of the protective case and the back side of the handheld device when the handheld device is inserted into the main opening of the protective case thereby securing the loop to the handheld device and protective case while leaving the manipulative portion of the loop at the outside of the protective case to facilitate manipulation of the handheld device and protective case.

US Pat. No. 10,455,923

ENTERAL FEEDING SYSTEM

1. A therapeutic accessory comprising:a stanchion, a plurality of mounting brackets, and a backpack;
wherein the plurality of mounting brackets attach to the stanchion;
wherein the stanchion and plurality of mounting brackets are attached to and contained within the backpack;
wherein the therapeutic accessory is configured for use with an enteral feeding system;
wherein the enteral feeding system comprises a feeding tube and a feeding machine;
wherein the therapeutic accessory is a luggage item that is configured to transport the enteral feeding system;
wherein the stanchion attaches the plurality of mounting brackets to the backpack;
wherein the stanchion comprises a ninth telescopic structure;
wherein each of the plurality of mounting brackets is a rectilinear structure that forms a right angle;
wherein each of the plurality of mounting brackets attaches to the stanchion;
wherein the span of the length of each of the plurality of mounting brackets is adjustable in two dimensions;
wherein each of the plurality of mounting brackets is used to support and contain the feeding machine within the backpack;
wherein the plurality of mounting brackets comprises a first mounting bracket, a second mounting bracket, a third mounting bracket, and a fourth mounting bracket;
wherein the backpack is a luggage item that is further defined with an anterior surface and a posterior surface;
wherein the ninth telescopic structure is a telescopic structure that comprises a seventeenth arm, an eighteenth arm, and a ninth detent;
wherein the position of the eighteenth arm relative to the seventeenth arm is held in position using the ninth detent;
wherein the seventeenth arm is a hollow prism that is further defined with an inner dimension;
wherein the eighteenth arm is a prism that is further defined with an outer dimension;
wherein the eighteenth arm is geometrically similar to the seventeenth arm;
wherein the span of the outer dimension of the eighteenth arm is lesser than the span of the inner dimension of the seventeenth arm such that the eighteenth arm inserts into the seventeenth arm;
wherein the length of the ninth telescopic structure is adjusted by adjusting the relative position of the eighteenth arm within the seventeenth arm;
wherein the seventeenth arm is further defined with a thirty-third end and a thirty-fourth end;
wherein the eighteenth arm is further defined with a thirty-fifth end and a thirty-sixth end.

US Pat. No. 10,455,920

PERSONAL PRODUCT APPLICATOR AND DISPENSER

1. A personal care product applicator comprises a plurality of cartridge assemblies arranged in series along a common axis, wherein each cartridge assembly includesa cartridge holder comprising a body that includes a cylindrical wall with an axial length, an axial bore in an upper surface proximate a top of the body, and an upper securement and a lower securement, for securing the plurality of cartridge assemblies in series; and
a product cartridge including:
(i) a cartridge that comprises a base and a plug that includes a cylindrical wall having an axial length with a bottom surface, which extends from a lower surface of the base, the plug configured for inserting into the axial bore for attaching the product cartridge to an attaching means of the cartridge holder; and
(ii) a volume of a personal care composition disposed to an upper surface of the base.

US Pat. No. 10,455,919

PEN AND PEN REFILL HAVING A LONGITUDINALLY EXTENDING GROOVE FOR TRANSFERRING DECORATIVE PARTICLES

Kuretake Co., Ltd., Nara...

1. A pen comprising:an ink reservoir configured to store an ink containing decorative particles;
a pen tip that has a proximal end to which the ink is supplied from the ink reservoir, a distal end opposite to the proximal end and configured to contact an ink coating target, and an outer circumferential surface extending from the proximal end to the distal end, and that is configured to apply the ink to the ink coating target; and
a holder part having a through hole through which the pen tip is inserted, the holder part being configured to at least partially hold the pen tip while exposing the distal end of the pen tip in the state where the pen tip is inserted through the through hole,
wherein the pen tip comprises a groove opening on the outer circumferential surface of the pen tip and extending from the proximal end to the distal end, and
wherein the holder part comprises: a first opening on an inner circumferential surface that defines the through hole and is capable of at least partially binding the pen tip; and an ink holding part constituted by a hollow that communicates with the first opening, extends radially outward from the first opening, and is capable of holding the ink from the ink reservoir.

US Pat. No. 10,455,915

PERSONAL WHEELED CONTAINER EXTERIOR SUPPORT SHELF

Russell Wilkin, Henderso...

1. A personal wheeled container, comprising:a body including a first end, a second end opposing the first end, a pair of opposing sides attaching the first end and the second end together, a top, and a bottom opposing said top, said body having an outside surface;
one or more wheels attached to said body;
a pull handle attached to said body;
an exterior support shelf removably attached to said outside surface of said body, said exterior support shelf including:
an elongated support member, said support member having a longitudinal axis and including:
an upper plate, an opposing lower plate, and a pair of side members that each extend along the longitudinal axis of said support member and attach said upper plate and said lower plate together, wherein said upper plate and said lower plate are attached together by said side members in a manner such that said upper plate and said lower plate are coplanar to one another and spaced apart to form a cavity between said upper plate and said lower plate that extends though said support member along the longitudinal axis of said support member;
a pair of opposing open ends, each open end forming an opening to said cavity; and
a shelf extension assembly, said shelf extension assembly including a pair of extendable/retractable shelf extensions that are attached to said support member, wherein each shelf extension can be extended from and retracted into said cavity through an open end of said support member to extend the length of said support member along its longitudinal axis beyond each side of the wheeled personal container.

US Pat. No. 10,455,913

LUGGAGE WITH AUTO-SUPPORT MECHANISM

1. A luggage, comprising a luggage body, a luggage wheel mounted to each of two opposite lateral sides of said luggage body and a support mechanism mounted to each of the said two opposite lateral sides of said luggage body corresponding to one respective said luggage wheel, wherein:said support mechanism comprises a locating shaft, a support member and a position-limiting member, said locating shaft being affixed to said luggage body and comprising a first locating groove and a second locating groove located on the periphery thereof and a stop rib disposed between said first locating groove and said second locating groove, said support member comprising a base block, a pivot hole located on said base block and pivotally coupled to said locating shaft, a support portion located on one end of said base block and an actuation portion located on an opposite end of said base block, said position-limiting member being mounted in said base block of said support member and transversely movable in and out of said pivot hole such that when said luggage body is tilted for movement by said luggage wheels, said position-limiting member is engaged in said second locating groove to lock said support member in a position where said actuation portion protrudes over a bottom side of said luggage body; when said luggage body is shifted from said tilted position to an erected position, said actuation portion is forced by the floor to bias said support member, causing movement of said position-limiting member out of said second locating groove over said stop rib into said first positioning groove and simultaneously forcing said support portion into abutment against the floor where the distance between said support portion and a front side of said luggage body is larger than the distance between the axis of said luggage wheels and the said front side of said luggage body.

US Pat. No. 10,455,907

BRACELET FOR A TIMEPIECE

GEOSATIS S.A., Le Noirmo...

1. A bracelet for a timepiece, the bracelet comprising:at least a first strap section and a second strap section, each strap section comprising a first end adapted to be joined to a watchcase and a second end joined to a foldable clasp, the foldable clasp being arranged such that it exhibits an unfolded state, in which said second ends are at a maximum separation, and a folded state, in which said second ends are maintained at a minimum separation, the first strap section or the second strap section comprising at least one electrical component,
first and second battery housings each adapted to receive a battery, the first and second battery housings being situated at said second ends of said first strap section and second strap section, respectively.

US Pat. No. 10,455,893

HYDROGEL WITH MESH FOR SOIL DEFLECTION

NIKE, INC., Beaverton, O...

1. An article of manufacture comprising:a substrate body;
a hydrogel-containing material having a first side secured to the substrate body and an opposing second side; and
a mesh component present on the second side;
wherein the mesh component covers a first surface portion of the hydrogel-containing material and leaves uncovered a second surface portion of the hydrogel-containing material, the mesh component covering the first surface portion has a first side defining a part of an external surface of the article and the uncovered second surface portion of the hydrogel-containing material defines another part of the external surface, and wherein the substrate body, the hydrogel-containing material, and the mesh component define a layered structure, wherein at least a portion of the mesh component is embedded into the substrate body, defining a first embedded portion.

US Pat. No. 10,455,891

TRAINING SHOE

1. A shoe, comprising:an upper shoe body having an opening, a tongue, a bottom, and a fastener;
an ankle stabilizer inserted into an upper perimeter of said opening, abutting an inner circumferential surface of said shoe upper and said tongue;
a cleat platform coextensive with a forward portion of said upper shoe body bottom and affixed to a bottom perimeter edge thereof; and
a plurality of cleats each coupled to said cleat platform, said each cleat is coupled to a selective location on said cleat platform;
wherein a heel portion of said upper shoe body bottom is exposed, without said cleats being coupled to said heel portion; and
wherein said fastener is securing said shoe to a foot of a user;
wherein said fastener is at least one hook-and-loop fastener material extending across said tongue of said upper shoe body;
wherein said at least one hook-and-loop fastener material;
wherein said ankle stabilizer comprises four protuberances defining an interior;
wherein said interior permits passage of a foot of said user therethrough when donning said shoe;
wherein said four protuberances are providing a cushioning effect and a stabilizing effect to an ankle of said user; and
wherein said ankle stabilizer is foam cushion material.

US Pat. No. 10,455,888

ATHLETIC SHOE HAVING A CROSS-TRAINING CONFIGURATION AND A WEIGHT-TRAINING CONFIGURATION

1. An athletic shoe selectively configurable between a weight-training configuration and a cross-training configuration, said athletic shoe comprising:an upper portion configured to receive a foot;
a first sole portion connected to the upper portion, the first sole portion having an inner surface and an outer surface opposite the inner surface, wherein the outer surface is configured to contact a training surface when the athletic shoe is in the cross-training configuration;
a second sole portion removably connected to the first sole portion when the athletic shoe is in the weight-training configuration, the second sole portion including a first surface, a second surface, and sides extending between the first surface and the second surface, wherein the first surface is configured to contact the training surface and the second surface is configured to contact the outer surface when the athletic shoe is in the weight-training configuration, wherein the first sole portion is configured to extend along the entire foot, and wherein the second surface is configured to contact the outer surface throughout the first sole portion such that the second sole portion is configured to extend along the entire foot and the entire second sole portion is positioned beneath the first sole portion when the second sole portion is connected to the first sole portion, wherein the second sole portion includes a toe portion and an open heel portion, the second sole portion having a minimum thickness at the toe portion and a maximum thickness at the open heel portion such that the second sole portion has a wedge shape, wherein the second sole portion does not include a side extending above the second surface in the open heel portion;
engagement members located in the open heel portion and configured to removably connect the second sole portion and the first sole portion, wherein the engagement members comprise a projection and an opening configured to receive the projection, wherein the projection extends from the second surface, and wherein the opening is defined by the outer surface; and
a strap connected to the second sole portion to secure the second sole portion in position when the athletic shoe is in the weight-training configuration, wherein the strap is configured to extend over a portion of the upper portion.

US Pat. No. 10,455,883

SHOCK ABSORBING HELMET LINER

1. A helmet liner comprising:an inner shell having a smooth curved exterior surface,
an outer shell surrounding the inner shell, the outer shell having a smooth curved interior surface with a space being defined between the inner and the outer shells, and
an array of springs arranged in the space between the inner and the outer shells to absorb impact to the outer shell and thus provide head protection for a person wearing the helmet liner;
wherein each spring, of the array of springs, is manufactured from a polymeric material and comprises:
a first spring half and a second spring half;
the first spring half has a first annular base located in a first plane and secured to the smooth curved exterior surface of the inner shell;
the second spring half has a second annular base located in a second plane spaced from the first plane. and the second annular base is secured to the smooth curved interior surface of the outer shell;
at least three arms interconnecting the first annular base with a waist portion, the at least three arms interconnecting the second annular base with the waist portion
each of the at least three arms having a serpentine configuration defined by sections having alternating curvature with plural reversals of curvature over a length of each of the at least three arms; and
a diameter of each of said first and second annular bases being at least twice as large as a diameter of the waist portion.

US Pat. No. 10,455,880

MOUNTING SYSTEM FOR EYEGLASSES AND HATS

1. A hat comprising:an enclosure that encloses part of a person's head;
a bill that extends outward from the enclosure to shade the person's eyes;
a first flexible tether on a first, lateral side of the bill, the first tether having a first end permanently connected to a bottom side of the bill adjacent a crown of the hat, the first tether having a second end with an opening therein sized to receive a first temple arm of a pair of eyeglasses passing therethrough during use of the first tether; and
a second flexible tether on an opposing, second lateral side of the bill and having a first end permanently connected to the bottom side of the bill adjacent a crown of the hat, the second tether having a second end with an opening sized to receive a second temple arm of the pair of eyeglasses passing therethrough during use of the second tether.

US Pat. No. 10,455,872

DISPOSABLE MEDICAL GOWN

MEDLINE INDUSTRIES, INC.,...

1. A gown, comprising:a non-woven fabric layer defining a head insertion aperture between a front portion and a rear portion, wherein a front portion length is greater than a rear portion length and the rear portion defines an opening configured to assist a user in donning the gown; and
one or more progressive perforations extending across the rear portion at least partially between the opening and the neck opening, the one or more progressive perforations being non-uniform in length and comprising at least a first score, a second score separated from the first score by a first length of material, the second score having a second score length that is longer than a first score length of the first score, and a third score separated from the second score by a second length of material, the third score having a third score length that is longer than the second score length, and configured to tear and split the rear portion when the front portion is pulled away from the user.

US Pat. No. 10,455,871

PERSONAL PROTECTIVE SYSTEM

SURGIVISOR LIMITED, Seve...

1. A protective apparatus for coverage of the face, neck and upper torso, comprising:a. a headpiece comprising a headband, a mandible guard and one or more support members, wherein the mandible guard is attached to the headband via the one or more support members, the headpiece further comprising at least one attachment point, wherein the at least one attachment point is located at a position on the headpiece selected from the group consisting of: the mandible guard, the one or more support members, and the combination thereof; and
b. a protective visor unit comprising
a visor, and
a skirt;
wherein the visor is attached to the skirt to form a single unitary piece,
wherein the protective visor unit is attached to the headpiece via the at least one attachment point,
wherein the skirt has an upper edge that is attached only to at least one of a bottom and sides of the visor, and
wherein the skirt is configured to extend downwardly around at least a part of the circumference of a user's head.

US Pat. No. 10,455,869

TECHNOLOGIES FOR TOOL CARRYING

Titan Retention LLC, Pin...

1. A device comprising:a vest including a front section and a back section;
a strap including a first strap end portion and a second strap end portion, wherein the first strap end portion is coupled to the front section;
a linear rack including a first rack end portion and a second rack end portion, wherein the first rack end portion is coupled to the first strap end portion; and
a pawl engaging the linear rack, wherein the pawl is coupled to the strap between the first strap end portion and the second strap end portion such that a distance between the pawl and the first strap end portion is decreased as the pawl engages the linear rack away from the second rack end portion towards the first rack end portion and such that the distance between the pawl and the first strap end portion is increased as the pawl disengages the linear rack away from the first rack end portion towards the second rack end portion, wherein the strap extends below an armpit of a wearer of the vest along a lateral side of the wearer when the wearer wears the vest.

US Pat. No. 10,455,865

EXPANDABLE SWADDLING GARMENT

1. An infant swaddling garment comprising a main body formed from a front surface and a rear surface joined together, and an intermediate area of material extending between the front and rear surfaces of said main body of said garment around substantially the entire outer periphery of said main body for defining a predetermined space between said front and rear surfaces around substantially the entire outer periphery of said main body, and means for selectively adjusting said predetermined space between said front and rear surfaces for selectively adjusting the volume of said main body of said infant swaddling garment.

US Pat. No. 10,455,860

ELECTRONIC CIGARETTE WITH INTEGRAL MOUTHPIECE

Guangrong Lin, Shenzhen ...

1. An electronic cigarette with an integral mouthpiece, comprising a vaporization assembly and a battery module connected mutually; the vaporization assembly comprises a mouthpiece with an opening, a vaporization tube, an outer ornamental sleeve, a connector and a vaporizer; wherein the mouthpiece is integrated with the vaporization tube, and the vaporization tube and the connector are telescoped within the outer ornamental sleeve; the vaporizer passes through the connector and is telescoped into the vaporization tube in a detachable manner; the connector is located at one end of the outer ornamental sleeve and connected to the battery module in a detachable manner; an airflow sealer is provided between an integral inner wall of the mouthpiece and the vaporization tube and an outer wall or a periphery of an end portion of the vaporizer;the airflow sealer is provided at an end portion of the mouthpiece close to the vaporization tube and located between the inner wall of the mouthpiece and the end portion of the vaporizer, and a through hole is provided in the center of the airflow sealer to serve as a part of the vapor airflow passage;
wherein the inner wall of the mouthpiece has an inward-curved flaring shape at an end being adjacent to the vaporization tube, and an outer wall of the airflow sealer has a similar flaring shape so as to be telescoped into the vaporization tube and fit the inner wall of the mouthpiece closely.

US Pat. No. 10,455,855

FRUIT SLICER AND JUICER APPARATUS AND METHOD

1. A hand-held fruit juicer comprisinga blade assembly comprising
a hinged elongated blade handle having a proximal end and a distal end, and
a blade extending from the blade handle, and
a spring;
a juicer portion comprising
a juicer handle having a proximal end and a distal end, and
two spaced apart squeezer elements extending from the juicer handle;
a cradle portion having a proximal end and a distal end, the cradle portion comprising
a cradle handle having a proximal end and a distal end, and
a dome receptacle formed in the cradle handle, the dome receptacle comprising a strainer, and
a plurality of fruit support ribs; and
a hinge element connecting the distal ends of the blade handle, juicer handle, and cradle handle,
such that
a portion of the cradle handle between the dome receptacle and the proximal end of the cradle handle is configured to be operable by hand,
a portion of the juicer handle between the squeezer elements and the proximal end of the juicer handle is configured to be operable by hand,
the blade is rotatable from a first position substantially nested between the spaced apart squeezer elements, and a second position substantially within the dome receptacle, and
the squeezer elements are rotatable from a first position withdrawn from the dome receptacle, and a second position substantially within the dome receptacle.

US Pat. No. 10,455,848

INDIVIDUAL FROZEN DRINK DISPENSER

Island Oasis Frozen Cockt...

1. An individual frozen drink dispenser comprising:a blender drive configured to drive operation of blades within a mixing cup;
a dispensing chamber configured to receive a frozen beverage container comprising frozen edible ingredients, the dispensing chamber comprising at least one dispensing roller configured to bear against at least one side of the frozen beverage container along a length of the frozen beverage container to squeeze the contents of the frozen beverage container from the frozen beverage container into the mixing cup for making a frozen drink; and
a controller coupled to the blender drive, the at least one dispensing roller, and a water pump to control the operation of the individual frozen drink dispenser.

US Pat. No. 10,455,835

FUNGICIDAL COMPOSITIONS FOR CONTROLLING LEAF SPOTS IN SUGAR BEETS

Dow AgroSciences LLC, In...

1. A method for the control and prevention of sugar beet leaf spot caused by Cercospora beticola (CERCBE) in a sugar beet plant, the method consisting essentially of: applying a fungicidally effective amount of a compound of Formula I, wherein the compound of Formula I is applied at a rate between about 100 g/ha and about 300 g/ha, and wherein said effective amount is applied to the plant

US Pat. No. 10,455,828

METHOD FOR MONITORING ONE OR MORE PEST TRAPS, SUCH AS RAT TRAPS

1. A method for monitoring when a pest trap is activated, said pest trap having (A) a moveable part and a fixed part between which an opening is defined and a step part is arranged, and (B) a switch connectable to a signalling device, the method comprising:when the moveable part is moved towards the fixed part, performing the following operations by the pest trap:
detecting an angle between the movable part and the fixed part;
causing information to be displayed by a remote communication unit which indicates that (a) the moveable part has been moved and a rat has gone into the pest trap and (b) the rat has a particular size corresponding to the angle.

US Pat. No. 10,455,825

PSYLLIUM FUMIGATED WITH METHYL BROMIDE

1. A method for providing fumigated and sanitized psyllium husk comprising:a. first separating psyllium husk from psyllium seed;
b. filling a fumigation chamber with the psyllium husk such that the chamber comprises about 35% to about 50% psyllium husk by volume;
c. fumigating the psyllium husk with at least about 40 g/m3 of methyl bromide for at least about 24 hours;
d. degassing the fumigation chamber for at least about 6 hours to form fumigated psyllium husk;
e. steam sanitizing the psyllium husk;wherein the fumigated psyllium husk comprises less than about 50 ppm inorganic bromide residue.

US Pat. No. 10,455,824

AGRICULTURAL CROP APPLICATION SYSTEM

Rick Eugene Lawrence, Bl...

1. A system for dispersing product along a ground surface of a field of crops using a mobile supporting boom spanning portions of the field of crops, comprising:a hose assembly extending from a proximal end to a distal end;
a swivel connection having a plate post rotatably connecting the proximal end to the supporting boom, wherein the swivel connection is linearly movable along a longitudinal axis of the plate post from a retracted position to an extended position, and wherein the swivel connection further comprising:
a boom extension plate interconnecting the hose assembly and the supporting boom, wherein the boom extension plate forms a bearing hole;
a tube bracket joined to the plate post, wherein the tube bracket attaches to the proximal end, wherein the plate post extends through the bearing hole so that a protruding portion of the plate post is provided, and wherein the spring is disposed on the protruding portion;
a spring disposed on the swivel connection so as to bias the swivel connection in the retracted position; and
an applicator connected to the distal end,
whereby the applicator drags along the ground surface.

US Pat. No. 10,455,822

FISHING ROD HOLDER

1. A fishing rod holder comprisinga tripod including an aft leg, a right leg and a left leg, each having a top end and a bottom end, the top end of each of the aft leg, right leg and left leg attached to a joint,
a pole rest extending from the joint, the pole rest comprising a pair of upright elements with a space therebetween for receiving and supporting a blank of a fishing rod,
an elongated longitudinal support extending linearly from the aft leg to a support foot, the support foot including a top and a bottom, the bottom of the support foot resting upon a surface when the fishing rod holder is in use, and the support foot including a channel extending from the top to the bottom and a cavity in the bottom of the support foot,
a deck lock coupled to the support foot, the deck lock comprising a handle, an elongated shaft having a top end and a bottom end, and a horizontal support extending from the bottom end of the elongated shaft and being substantially perpendicular to the elongated shaft, a spring biasing the horizontal support towards the support foot, and the elongated shaft of the deck lock extending through the channel of the support foot, and the deck lock being rotatable relative to the support foot and capable of reciprocating movement relative to the support foot, and the deck lock being pivotable relative to the support foot between a stowed position and a deployed position, and the deck lock occupying the bottom cavity when the deck lock is in the stowed position and the deck lock being outside of the bottom cavity when the deck lock is in the deployed position,
an L-shaped coupling having an upright portion and a rearward extending portion, the elongated longitudinal support being coupled to the aft leg with the L-shaped coupling, the bottom end of the aft leg being attached to the upright portion and a pivot pin attaching the elongated longitudinal support to the rearward extending portion, the elongated longitudinal support being capable of pivoting rotation relative to the L-shaped coupling about the pivot pin, and
a tube coupled to the support foot, said tube having an open end towards the pole rest, said tube being sized and shaped to receive a handle of the fishing rod while the pole rest supports the blank of the fishing rod.

US Pat. No. 10,455,818

BIRD FEEDER

1. A squirrel resistant bird feeder, comprising:a vertically disposed and hollow cylindrical feed container having an open upper end and an open lower end;
a feed tray mounted to said feed container at said lower end thereof which is configured to receive feed from said feed container;
said feed container having a feed inlet structure at its upper end which has an upper side;
said feed inlet structure having a plurality of feed openings formed therein which are configured to permit feed to pass downwardly therethrough into said feed container;
said feed inlet structure having a plurality of radially spaced-apart tapered shoulders extending upwardly therefrom;
a vertically disposed hanger member having upper and lower ends;
said lower end of said hanger member being secured to said feed inlet structure;
said hanger member extending vertically upwardly from said feed inlet structure and said feed container;
an elongated and vertically disposed cylindrical mesh shroud having an upper end and a lower end;
said shroud having a feed tray blocking member secured to and extending around said shroud above said lower end of said shroud;
said shroud enclosing said feed container and said feed tray;
said shroud having a plurality of perches secured thereto at its said lower end;
a cover fixedly secured to said upper end of said shroud;
said cover having an upper side and a lower side;
said cover including an outer end which has a diameter greater than the diameter of said shroud;
said cover having a central opening formed therein;
said hanger member extending upwardly through said central opening in said cover whereby said upper end of said hanger member is positioned above said cover;
said upper end of said hanger member being configured to be operatively secured to an overhead support;
said shroud being vertically movable between an upper position and a lower position with respect to said feed container;
a coil spring having a movable upper end and a stationary lower end;
said coil spring being positioned between said feed inlet structure and said lower side of said cover;
said lower end of said coil spring extending around said tapered shoulders of said feed inlet structure and being in direct engagement therewith;
said upper end of said coil spring being in operative engagement with said lower side of said cover;
said coil spring yieldably maintaining said shroud in its said upper position;
said shroud being movable from its said upper position to its said lower position upon a squirrel climbing onto said shroud or said perches whereby said upper end of said coil spring is compressed downwardly towards said stationary lower end of said coil spring; and
said feed tray blocking member being positioned outwardly of said feed tray, when said shroud is in said lower position, to deny access to said feed tray.

US Pat. No. 10,455,812

PET EXCREMENT CATCHER

1. A collection device comprising:an extension shaft, a capture structure, a hinge mechanism, and a grip;
wherein the capture structure, the hinge mechanism, and the grip attach to the extension shaft;
wherein the collection device is adapted for use with a companion animal;
wherein the collection device is a device for capturing an elimination from the companion animal;
wherein the collection device is adapted for use with a client;
wherein the collection device is an extension apparatus that extends the reach between the companion animal and the client;
wherein the hinge mechanism is a mechanical device;
wherein the hinge mechanism is a rotating structure that attaches an upper jaw to the end of an inferior arm that is distal from a medial arm;
wherein the hinge mechanism attaches the upper jaw to the inferior arm such that the upper jaw rotates from a position of alignment with a bottom jaw to a position parallel to the center axis of the inferior arm;
wherein a superior arm, the medial arm, and a detent combine to form a telescopic structure;
wherein the superior arm is a hollow prism-shaped structure that is further defined with an inner dimension;
wherein the medial arm is further defined with an outer dimension;
wherein the superior arm and the medial arm are geometrically similar;
wherein the outer dimension of the medial arm is less than the inner dimension of the superior arm such that the medial arm inserts into the superior arm in a telescopic manner;
wherein the telescopic arrangement of the extension shaft allows the length of the extension shaft adjusts by adjusting the relative position of the medial arm within the superior arm;
wherein the detent is a mechanical device that connects and secures the superior arm to the medial arm;
wherein the extension shaft is an adjustable structure;
wherein the extension shaft adjusts the reach between the client and the companion animal.

US Pat. No. 10,455,807

PET FOUNTAINS

Pet Mate Ltd., Surrey (G...

1. A pet fountain comprisingan upper bowl;
a base including a lower bowl, and a carrier wall that separates the lower bowl into first and second side regions;
the upper bowl being removeably securable to the base and the carrier wall so that the upper bowl is elevated above the level of the base and above the first side region; and
wherein the second side region of the lower bowl is sufficiently large to accommodate the upper bowl when the upper bowl is not secured to the base.

US Pat. No. 10,455,774

HAND-HELD MINIATURE AUTOMATIC TREE INJECTION DEVICE

Arborjet, Inc., Woburn, ...

1. A method for injecting an agent into a tree for use by a user, the method comprising the following steps:(a) providing a portable hand-holdable tree injection device capable of delivering a variable but continuous injection of a pre-chosen agent at different injection pressures into the tree's trunk, wherein the device is powered by a portable air tank or regulator, the device weighs between 1-4 pounds, and the device comprises a clear metering barrel, an air piston, a flow control valve, an injector check valve, a needle at the end of the device, and an on/off switch;
(b) adjusting the dose of the agent to be injected into the tree by using the clear metering barrel to identify the dose to be applied;
(c) adjusting the air pressure to be between about 1 psi-125 psi;
(d) inserting the needle into the tree;
(e) turning the on/off switch to the on position, and then releasing the switch, such that the user is not required to hold the on/off switch in the on position throughout injection, wherein turning the on/off switch to the on position opens the injector check valve to allow the agent to be injected into the tree;
(f) thereby injecting the tree with the agent.

US Pat. No. 10,455,772

LIGHT EMITTING DEVICE AND METHOD OF REGULATING PLANT GROWTH USING THE SAME

BOE TECHNOLOGY GROUP CO.,...

1. A light emitting device, comprising a light source, a drive module and a dimming control module; whereinthe drive module is connected to the light source and the dimming control module, the dimming control module is configured to output a control signal to the drive module, the drive module is configured to adjust brightness of the light source according to the control signal, and
the dimming control module comprises a first controller configured to perform pulse width modulation (PWM), wherein
by means of pulse width modulation, the first controller sequentially outputs;
a high-level control signal with a duration of h1;
a control signal with a duration of h2 in transition from a high level to a low level;
a low-level control signal with a duration of h3; and
a control signal with a duration of h4 in transition from the low level to the high level.

US Pat. No. 10,455,771

PLANT GROWTH ACCELERATION SYSTEM

eAgritech, Inc., Tokyo (...

1. A plant growth acceleration system is composed of an electron generation means that generates electrons and an electron radiation means that radiates electrons to a plant growth area, and the plant growth acceleration system is characterized as follows:the plant growth area is in an electrically grounded condition;
the electron generation means has a transformer circuit that transforms AC power inputted to a primary circuit to high voltage and outputs from a secondary circuit; a first terminal of the secondary circuit is connected to the primary circuit, and a second terminal of the secondary circuit is connected to the electron radiation means; according to plus/minus inversion cycles of the AC power, in the state of the first terminal being in positive potential current from the second terminal to the electron radiation means is blocked, and in the state of the first terminal being in negative potential the current returns from the first terminal to the primary circuit; thus
only in the state of the first terminal being in negative potential, according to the inversion cycles, the electrons are transmitted cyclically from the second terminal to the electron radiation means;
the electron radiation means includes electron transmission parts that have electron radiation parts grounded to the plant growth area;
the electron transmission parts extend linearly;
the electron radiation parts extend linearly and are continuously grounded to the plant growth area; and
the electron radiation parts radiate only the electrons along the electron radiation parts, and accelerate plant growth.

US Pat. No. 10,455,765

METHOD AND SYSTEM FOR CONTROLLING THE HEIGHT OF AGRICULTURAL IMPLEMENT RELATIVE TO THE GROUND

CNH Industrial America LL...

1. A method for automatically controlling a height of an implement of an agricultural work vehicle relative to a ground surface, the method comprising:monitoring, with at least one computing device, the height of the implement relative to the ground surface;
determining, with the at least one computing device, an implement height error by comparing the height of the implement with a predetermined target height;
calculating, with the at least one computing device, a proportional signal gain based on the implement height error, the proportional signal gain varying with the implement height error, wherein calculating the proportional signal gain comprises at least one of:
applying, with the at least one computing device, a discontinuous function such that the proportional signal gain is equal to a predetermined constant when the implement height error is less than a predetermined threshold error; or
applying, with the at least one computing device, a saturation function such that the proportional signal gain does not exceed a predetermined maximum gain;
calculating, with the at least one computing device, a proportional signal based on the implement height error raised to a power greater than one, wherein the proportional signal is based on a product of the implement height error and the proportional signal gain to raise the implement height error to the power greater than one; and
adjusting, with the at least one computing device, the height of the implement relative to the ground surface based on the proportional signal.
US Pat. No. 10,459,359

TONER BINDER AND TONER

SANYO CHEMICAL INDUSTRIES...

1. A toner binder comprising:a non-linear polyester modified resin (A),
wherein the non-linear polyester modified resin (A) is a modified resin having one or more carbon-carbon bonds crosslinking polyesters,
wherein the toner binder has a loss tangent tan ? of 2 to 20 in the entire temperature range of 110° C. to 130° C.,
wherein the polyester comprises a polyester (A1) having carbon-carbon double bonds, and the polyester (A1) having carbon-carbon double bonds has a glass transition temperature TgA1 of ?35° C. to 43° C.
US Pat. No. 10,457,822

INK COMPOSITION FOR MARKING RELEASE-TREATED SURFACE, AND PROTECTIVE FILM CONTAINING SAME

LG CHEM, LTD., Seoul (KR...

1. An ink composition for marking on a release-treated surface, comprising:a binder resin based on an acryl or methacryl resin with a glycidyl group introduced as a functional group thereinto;
a dye; and
an organic solvent,wherein the binder resin;has a glass transition temperature of 40° C. or higher and has a glycidyl content of 400-600 g/eq as converted into epoxy equivalent weight; and
is present in an amount of 2-10% by weight, based on a total weight of the ink composition.
US Pat. No. 10,457,824

METHOD OF INKJET PRINTING

EASTMAN KODAK COMPANY, R...

1. A method for inkjet printing, comprising:inkjet printing an aqueous inkjet ink composition onto a substrate to provide an inkjet printed image, wherein the aqueous inkjet ink composition has a viscosity of at least 1 centipoise and up to and including 100 centipoise at 25° C., and comprises:
(a) an aqueous solvent medium,
(b) a non-crosslinked, crosslinkable polyurethane having an acid number of at least 20 and up to and including 40, and a glass transition temperature (Tg) of up to and including 40° C.,
the non-crosslinked crosslinkable polyurethane derived from:
1) an aromatic diisocyanate; and
2) a diol mixture of at least D1, D2, and D3 diols, and optionally including a D4 diol,
wherein:
the D1 diol comprises a C3 to C7 aliphatic group between two hydroxy groups, and at least one pendant carboxy group or pendant neutralized carboxy group,
the D2 diol comprises a chain of one or more repeating C2 to C6 alkylene oxide groups and has a weight average molecular weight of at least 250 and up to and including 3,000,
the D3 diol is an alkoxylated bisphenol A or an aliphatic cyclic diol that is present in an amount of at least 5 mol %, based on the total molar amount of the D1 through D4 diols in the diol mixture, and
the D4 diol is a hydroxy-terminated polybutadiene having a weight average molecular weight of at least 1000, and when present, is present in an amount of at least 0.1 mol % and up to and including 5 mol %, based on the total molar amount of the D1 through D4 diols in the diol mixture;
(c) a dispersed pigment colorant;
(d) a humectant or organic co-solvent, and
(e) optionally, a crosslinking agent.
US Pat. No. 10,457,827

AQUEOUS, POLYVINYL ALCOHOL STABILIZED VINYL ACETATE-ETHYLENE-COPOLYMER DISPERSION HAVING HIGH FILLER COMPATIBILITY FOR CARPET COATING COMPOSITIONS

Wacker Chemie AG, Munich...

1. A carpet coating composition for consolidating carpets, which comprises an aqueous vinyl acetate-ethylene copolymer dispersion obtained via free-radically initiated emulsion polymerization, in an aqueous medium, of vinyl acetate and ethylene and optionally further ethylenically unsaturated comonomers, wherein the dispersion comprises a stabilizing system comprising from 5 to 10 wt %, based on total comonomers, of one or more partially hydrolyzed and low molecular weight polyvinyl alcohols having a hydrolysis degree of respectively 80 to 95 mol % and a Hoeppler viscosity, in 4% aqueous solution, of respectively 1 to 5 mPas (DIN 53015 Hoeppler method at 20° C.) and comprising from 100 to 1400 wt % of filler, based on 100 wt % of vinyl acetate-ethylene copolymer (solids/solids).
US Pat. No. 10,456,290

LOW-MODULUS ELASTOMERIC COMPOSITIONS AND ARTICLES MADE THEREWITH

1. An elastomeric article having at least one layer, said at least one layer consisting essentially of 1) at least one styrene-block-ethylene-co-butylene-block-styrene (SEBS) film-forming polymer, and optionally, a polymeric material selected from the group consisting of rubber latex (NRL), synthetic polyisoprene (PI), polyurethane (PU), silicone, styrene-co-butadiene (SB), styrene-co-isoprene (SI), styrene-block-ethylene-co-propylene-block-styrene (SEPS), styrene-block-ethylene-co-ethylene-propylene-block-styrene (SEEPS), and mixtures thereof; 2) at least one plasticizer present in an amount of about 100 to less than 250 parts plasticizer per hundred parts of rubber (phr), and 3) optionally at least one filler selected from calcium carbonate, talc, titanium oxide, silica, clay, carbon black, magnesium carbonate, alumina, and mixtures thereof, wherein said article has a modulus of less than 1.2 MPa at 500% extension, and a thickness of about 66 to no more than 270 microns, wherein said article is a condom.
US Pat. No. 10,457,834

CHROME FREE COATING COMPOSITION HAVING EXCELLENT BLACKENING RESISTANCE AND CORROSION RESISTANCE, AND SURFACE-TREATED STEEL SHEET

POSCO, Pohang-si, Gyeong...

1. A chromium-free coating composition for a magnesium-containing steel sheet having high blackening resistance and corrosion resistance, the chromium-free coating composition comprising a waterborne silane-modified polyurethane in an amount of 20 wt % to 70 wt %, a hardener in an amount of 0.5 wt % to 5 wt %, a blackening inhibitor in an amount of 0.5 wt % to 5 wt %, a corrosion inhibitor in an amount of 0.5 wt % to 5 wt %, a lubricant in an amount of 0.5 wt % to 5 wt %, and a balance of a solvent,wherein the blackening inhibitor comprises a molybdenum-based compound, and the waterborne silane-modified polyurethane has a number average molecular weight within a range of 10,000 to 60,000.
US Pat. No. 10,455,789

SOYBEAN VARIETY 5PLSB92

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PLSB92, representative seed of the variety having been deposited under ATCC Accession Number PTA-125066.
US Pat. No. 10,455,790

SOYBEAN VARIETY 5PSGM88

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PSGM88, representative seed of the variety having been deposited under ATCC Accession Number PTA-125067.
US Pat. No. 10,457,842

CURABLE COMPOSITION

LG CHEM, LTD., Seoul (KR...

1. A curable composition, comprising a curable adhesive resin, a silane coupling agent at less than 2 parts by weight, with respect to 100 parts by weight of the curable adhesive resin, and a high-molecular-weight resin of which a weight-average-molecular weight is 20,000 or more, and of which a content of halogen ions is 1,000 ppm or less as measured according to ASTM D 7359:2008, wherein the high-molecular-weight resin comprises a phenoxy resin, the composition satisfying the following Equations 1 and 2:X?1,000 ppm  [Equation 1]
Y?1,000 ppm,  [Equation 2]
wherein X in Equation 1 is an amount of volatile organic compounds, which is measured by preparing a film with the curable composition, maintaining 50 mg of the film sample at 150° C. for 1 hour, and using purge and trap-gas chromatography/mass spectrometry, and
Y in Equation 2 is an amount of ionic substances contained in the curable composition, which is obtained by preparing a film with the curable composition, and measuring 50 mg of the film sample according to ASTM D 7359:2008,
wherein a moisture content of a film sample formed of the curable composition is 0.01 wt % to 1 wt %, and the moisture content of the film sample is measured according to ASTM D3451-06 (2012) after preparing a film with the curable composition, and maintaining 50 mg of the film sample under conditions of 25° C. and a relative humidity of 50% for 24 hours.
US Pat. No. 10,456,816

DEMILITARIZATION OF HC SMOKE ORDNANCES

1. A method for demilitarization of HC smoke ordnance comprising hexachloroethane (HCE), zinc oxide, and granular aluminum in a metal container, said method comprising:open or penetrate the container and extract the HCE by contact with a solvent which solubilizes and extracts the HCE from the zinc oxide and aluminum; and
wherein the solvent is selected from the group consisting of: chloroform, benzene, carbon disulfide, carbon tetrachloride, and perchloroethylene.
US Pat. No. 10,457,843

MAGNETIC FLOORING SYSTEM ADHESIVE COMPOSITION

1. A cured composition derived from a mixture comprising the following components:(a) a first component comprising a polymerisable isocyanate;
(b) a second component comprising a castor oil; the ratio of the polymerisable isocyanate to the castor oil being between about 20% and about 45% by weight; and
(c) magnetic and/or magnetizable particles mixed into at least one of the first component and the second component;wherein the magnetic and/or magnetizable particles is in the range of between about 30% and about 80% by weight of the total composition.
US Pat. No. 10,455,792

SOYBEAN CULTIVAR TMG4177

1. A seed of soybean inbred line designated TMG4177, or a part thereof, wherein representative seed of the line have been deposited under ATCC Accession No. PTA-125109.
US Pat. No. 10,457,848

SELF-REPAIRING CEMENTS

SCHLUMBERGER TECHNOLOGY C...

1. A cement slurry, comprising:thermoplastic block-polymer particles selected from the group consisting of styrene-isoprene-styrene polymer particles, styrene-butadiene-styrene polymer particles, and mixtures thereof;
wherein the thermoplastic block-polymer particles have a particle size between 100 ?m and 900 ?m, and a tensile strength between 1.5 MPa and 40 MPa,
wherein the slurry further comprises an aqueous inverse emulsion of particles comprising a betaine group, poly-2, 2, 1-bicyclo heptene (polynorbornene), alkylstyrene, crosslinked substituted vinyl acrylate copolymers, diatomaceous earth, vinyl acetate rubber, polychloroprene rubber, acrylonitrile butadiene rubber, hydrogenated acrylonitrile butadiene rubber, ethylene propylene diene monomer, ethylene propylene monomer rubber, styrene/propylene/diene monomer, brominated poly(isobutylene-co-4-methylstyrene), chlorosulphonated polyethylenes, brominated butyl rubber, chlorinated butyl rubber, chlorinated polyethylene, epichlorohydrin ethylene oxide copolymer, ethylene acrylate rubber, ethylene propylene diene terpolymer rubber, sulphonated polyethylene or substituted styrene acrylate copolymers or combinations thereof;
the cement slurry to be pumped in a well with a borehole penetrating a methane-containing formation, wherein methane is present at a concentration higher than 91 mol % and at a pressure higher than 3.5 MPa; and
wherein the thermoplastic block-polymer particles swell when in contact with the methane, after microannuli, cracks or defects occur in a cement sheath.
US Pat. No. 10,457,850

REDUCED CORROSION IRON SULFIDE SCALE REMOVING FLUIDS

SAUDI ARABIAN OIL COMPANY...

1. A low-corrosivity composition suitable for dissolving scale on metal, where the scale comprises iron sulfide scale, the composition consisting of:an aqueous hydrogen peroxide solution comprising hydrogen peroxide, where the hydrogen peroxide is present at about between 0.5% and about 1.5% by weight of the composition; and
an acidic solution comprising at least one acid, where the acidic solution comprises acetic acid present at about between 0.25% and about 2.5% by weight of the composition, where the hydrogen peroxide and acid are present at concentrations such that the hydrogen peroxide does not break down to form visible bubbles at about room temperature,
where the hydrogen peroxide and acid are present at concentrations such that the iron sulfide scale is removed from the metal with iron sulfide scale, after the composition contacts the metal and iron sulfide scale at an elevated temperature greater than room temperature, and
where the hydrogen peroxide and acid are present at concentrations such that pitting is not caused on the metal, the metal comprising carbon steel, and where the balance of the composition is at least about 90 weight % water to form a dilute, low-corrosivity solution mixture.
US Pat. No. 10,457,852

SILOXANE SURFACTANT ADDITIVES FOR OIL AND GAS APPLICATIONS

Flotek Chemistry, LLC, H...

1. A well treatment additive comprising:a siloxane surfactant in an amount between about 10 wt % and about 15 wt % versus the total well treatment additive, wherein the siloxane surfactant has a formula selected from the group consisting of: MDa(D?R1)bM (formula 1) and (M?R1)Da(M?R1) (formula 2)
wherein “R1” represents an organic radical comprising —(CH2)n—(OCH2CH2)x—(OCH(CH3)CH2)y—OR3, in which “n” is between 3 and about 11, “x” is between 3 and about 30, “y” is between 0and about 30, and “R3” is —H;
wherein “M” represents Me3SiO1/2, D represents —Me2SiO—, “M?R1” represents Me2(R1)SiO1/2—, “D?R1” represents —Me(R1)SiO—, and “Me” represents —CH3;
wherein for formula 1, “a” is 0-200 and “b” is 1-20;
wherein for formula 2, “a” is 4-50; wherein the siloxane surfactant is a trisiloxane ethoxylate graft-type copolymer
a hydrocarbon surfactant in an amount between about 10 wt % and about 35 wt % versus the total well treatment additive, wherein the hydrocarbon surfactant is selected from the group consisting of polyoxyethylene alky ethers, dialkyl sulfosuccinates, alkyl sulfates, sulfonates, carboxylates, amine oxides, primary alkylamines, dialkyl secondary amines, ethoxylated fatty amines, and combinations thereof;
a solvent, wherein the solvent is a terpene hydrocarbon in an amount between about 5 wt % and about 40 wt % versus the total well treatment additive; and
an aqueous phase.
US Pat. No. 10,457,600

METHOD FOR REDUCING AGGLOMERATION IN GYPSUM PLASTER OR FILLING COMPOSITIONS COMPRISING CELLULOSE ETHER

Dow Global Technologies L...

1. A method for providing a modified gypsum plaster or filling composition having reduced agglomeration in comparison to a gypsum plaster or filling composition comprising a water soluble cellulose ether in a specified amount X, where the specified amount is from 0.1 to 1.0 weight percent based on the total dry weight of said composition components, said method comprising:a) forming a dry mortar comprising gypsum binder; water soluble cellulose ether in an amount of X minus Y; and gelatin in an amount Y, wherein Y is from 0.02X to 0.30X; and
b) combining said dry mortar with water to form a modified gypsum plaster or filling composition;
wherein said cellulose ether is an alkylhydroxyalkylcellulose, a hydroxyalkyl cellulose, or a mixture thereof;
wherein said cellulose ether has a median particle diameter DOP (50,3) of from 25 ?m to 45 ?m.
US Pat. No. 10,457,862

HYDRATION OF ASSOCIATIVE POLYMERS

RHODIA OPERATIONS, Paris...

1. A process for hydration of associative polymers (P), resulting in the preparation of an aqueous composition comprising said associative polymers (P) in the form of a solution or of a gel, the process comprising a step (E) of adding water to a solid composition (C) comprising said associative polymers (P) and surfactants (S) suitable for improving the hydration of these polymers, the hydration being carried out in less than five hours,wherein said solid composition (C) is as obtained by drying an aqueous composition comprising a mixture of the associative polymers (P) in the form of a gel in the hydrated state and of the surfactants (S) obtained by post-addition of the surfactants (S) to associative polymers (P) resulting from a micellar polymerization wherein the associative polymers (P) are synthesized according to a controlled micellar radical polymerization step in which the following are brought into contact, in an aqueous medium (M):hydrophilic monomers, dissolved or dispersed in said aqueous medium (M); hydrophobic monomers in the form of a micellar solution; at least one radical polymerization initiator; and at least one radical polymerization control agent.
US Pat. No. 10,457,624

SYSTEMS AND PROCESSES FOR THERMOLYSIS OF POLYLACTONES TO PRODUCE ORGANIC ACIDS

Novomer, Inc., Boston, M...

1. A process for producing an organic acid product, wherein the process comprises:a. introducing epoxide reagent and carbon monoxide reagent to a reaction vessel through a feed stream inlet, the reaction vessel comprising a separation chamber positioned above and in direct communication with a thermolysis chamber;
b. contacting the epoxide reagent and the carbon monoxide reagent with a carbonylation catalyst to produce a beta-lactone intermediate;
c. polymerizing the beta-lactone intermediate with a polymerization initiator in the presence of a metal cation to produce a polylactone product; and
d. heating the polylactone product under thermolysis conditions to produce the organic acid product.
US Pat. No. 10,456,342

SUNSCREEN/INSECT REPELLANT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

Sunsect, Inc., Tallahass...

1. A combination sunscreen and insect repellant composition comprising:at least 15 weight percent (wt %) of diethyl toluamide (or N,N-Diethyl-3-methylbenzamide or DEET);
two or more sunscreen components, each of said two or more sunscreen components being capable of absorbing ultraviolet light rays, and wherein said two or more sunscreen components comprise (a) 1-(4-methoxyphenyl)-3-(4-tert-butylphenyl)propane-1,3-dione and (b) (RS)-2-ethylhexyl (2E)-3-(4-methoxyphenyl)prop-2-enoate; and
a polymeric binder system;
wherein all weight percents are based on a total weight of said composition.
US Pat. No. 10,455,830

PYRETHROID FORMULATIONS

Vive Crop Protection Inc....

1. An aqueous formulation comprising:nanoparticles comprising a polymer and a pyrethroid compound with an average diameter of between about 1 nm and about 500 nm;
wherein the polymer is a polyelectrolyte copolymer comprised of at least about 50 weight percent methacrylic acid monomers, acrylic acid monomers or combinations thereof;
between about 0.05 weight percent and about 10 weight percent of an anti-caking agent;
between about 0.1 weight percent and about 1 weight percent of an anti-foaming agent;
between about 0.01 weight percent and about 0.1 weight percent of a preservative; and
water;
wherein the polymer and the pyrethroid compound together comprise between about 5 weight percent and about 50 weight percent of the aqueous formulation.
US Pat. No. 10,456,343

MICROEMULSION COMPOSITIONS COMPRISING POLYDATIN AND METHOD OF USE

1. A microemulsion composition comprising:(a) 0.1 to 5 wt. % of polydatin;
(b) optionally, 0.1 to 10 wt. % of niacinamide;
(c) optionally, 0.1 to 3 wt. % of baicalin;
(d) at least 0.5 wt. % of one or more oils;
(e) water; and
(f) up to 10 wt. % of one or more emulsifiers, wherein the weight ratio of the total amount of the one or more emulsifiers to the total amount of the one or more oils is 1.7 to 2.5 (one or more emulsifiers/one or more oils).
US Pat. No. 10,456,344

HAIR COMPOSITION

CONOPCO, INC., Englewood...

1. An oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth,wherein the oral or topical composition comprises ?9% w/w ?-sitosterol,
and wherein the nuclear factor erythroid-2 related factor 2 agonist comprises granilin and the liver X receptor agonist comprises a compound selected from the group consisting of 22(R)-hydroxycholesterol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzeneacetic acid hydrochloride (GW 3965) and/or salts thereof, and stigmasterol; or wherein the nuclear factor erythroid-2 related factor 2 agonist comprises 1 ?M sulforaphane and the liver X receptor agonist comprises 10 ?M 22(R)-hydroxycholesterol, and
wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90% w/w catechins, and
wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, and
wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and
wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.
US Pat. No. 10,457,884

MIXED DETERGENT COMPOSITION FOR INTAKE VALVE DEPOSIT CONTROL

Afton Chemical Corporatio...

1. A detergent additive package for an unleaded gasoline fuel comprising a Mannich base detergent mixture, wherein the mixture comprises a first Mannich base detergent component having a tertiary amino group and derived from an aliphatic linear, branched, or cyclic diamine having one primary or secondary amine group and one tertiary amino group in the molecule and a second Mannich base detergent component derived from a monoamine, wherein a weight ratio of the first Mannich base detergent to the second Mannich base detergent in the mixture ranges from about 1:6 to about 3:1.
US Pat. No. 10,457,629

THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAME

Yale University, New Hav...

1. A method of ameliorating a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of hypertriglyceridemia, fatty liver, and insulin resistance, the method comprising administering to the subject a therapeutically effective amount of 2,4-dinitrophenyl methyl ether or a solvate thereof.
US Pat. No. 10,456,348

AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN-CONTAINING FIBERS

10. A method for the temporary deformation of keratin-containing fibers, in which the keratinic fibers are acted upon by a cosmetic composition according to claim 1 and temporarily fixed in their shape.
US Pat. No. 10,457,888

LUBRICATING MEMBERS FOR RAZOR CARTRIDGES

Braun GMBH, Kronberg (DE...

1. A razor cartridge comprising:a) a razor cartridge housing containing at least one blade;
b) a guard member positioned on the razor cartridge housing forward of the at least one blade;
c) a cap positioned on the razor cartridge housing aft of the at least one blade, wherein during a shaving stroke skin is contacted by the guard prior to the at least one blade, and the at least one blade prior to contacting the cap; said cap comprising at least one lubricating member, each lubricating member comprising:
i) from about 25% to about 65% by weight of said lubricating member of a lipophilic structurant or mixture thereof, wherein said lipophilic structurant is selected from C14-C20 alcohols, microcrystalline wax, stearyloxytrimethylsilane, and mixtures thereof,
ii) from about 20% to about 60% by weight of said lubricating member of a silicone polyether block copolymer, wherein said silicone polyether block copolymer consists essentially of repeating units of polyethylene oxide, silicone, and polypropylene oxide, at levels of: about 1% to about 50%, by weight of polyethylene oxide, from about 20% to about 90% by weight of polypropylene oxide and from about 1% to about 20% by weight of silicone, and has a ratio of polyethylene oxide units to polypropylene oxide units to silicone units of from 20:65:15, and
iii) from about 20% to about 40% by weight of said lubricating member of a liquid phase, wherein said liquid phase comprises a component selected from natural oil, synthetic oil, natural butter, triglyceride, petrolatum, silicone, and mixtures thereof;
iv) wherein said silicone polyether block copolymer is free of any additional alkyl chains; and
v) wherein said lubricating member is substantially free of soap.
US Pat. No. 10,455,837

COMPLEXES OF CLOQUINTOCET AND AMINE-CONTAINING POLYMERS OR OLIGOMERS

Dow ArgoSciences LLC, In...

1. A composition comprising a safener complex and a pesticide, wherein:the safener complex comprises cloquintocet acid, or a salt thereof, and an amine-containing polymer or oligomer;
the weight ratio of the cloquintocet acid, or salt thereof, to the amine-containing polymer or oligomer ranges from 1:2 to 10:1; and
the amine-containing polymer or oligomer includes a branched, spherical polyethyleneimine.
US Pat. No. 10,456,606

DECOLORIZATION OF COLORED KERATINIC FIBERS

1. A multi-component packaging unit (kit of parts) for the reductive decolorization of colored keratinic fibers comprising, packaged separately from one another,(I) a container (A) containing a cosmetic agent (a),
(II) a container (B) containing a cosmetic agent (b), and
(III) a container (C) containing a cosmetic, aqueous agent (c), with
the agent (a) in container (A) comprising 85.0 to 100 wt % with respect to the total weight of agent (a), of
(a1) one or more reducing agents selected from the group consisting of sodium dithionite, zinc dithionite, potassium dithionite, sodium sulfite, sodium hydrogen sulfite, potassium sulfite, potassium hydrogen sulfite, ammonium sulfite, sodium thiosulfate, potassium thiosulfate, ammonium thiosulfate, hydroxymethane sulfinic acid, aminomethane sulfinic acid, cysteine, thiolactic acid, sulfanylacetic acid (thioglycolic acid), ascorbic acid, and mixtures thereof,
the agent (b) in container (B), comprises
(b1) water and
(b2) one or more acids selected from inorganic and/or organic acids, and
agent (c) in container (C) comprising
(c1) one or more acids selected from the group consisting of malonic acid, oxalic acid, and mixtures thereof, and
(c2) methanesulfonic acid, wherein the total amount of the one or more acids (c1) and the methanesulfonic acid (c2) is present in agent (c) in a total quantity of 2.0 to 20.0 wt % with respect to the total weight of agent (c) and
(c3) one or more zwitterionic and/or amphoteric surfactantswhereinthe agent (a) in container (A) is a water-free agent,
the agent (b) in container (B) is an aqueous agent having a pH of 1 to 6, measured using a Schott N61-type glass electrode at a temperature of 22° C.,
and
the agent (c) in container (C) has a pH of 0.5 to 4.0 measured using a Schott N61-type glass electrode at a temperature of 22° C.
US Pat. No. 10,457,890

PHOSPHOLIPASE C

DSM IP ASSETS B.V., Heer...

1. A process for hydrolysing one or more phospholipids comprising:a) separating the one or more phospholipids from an oil;
b) incubating the one or more phospholipids with a polypeptide having phospholipase C activity selected from the group consisting of:
i) a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
ii) a polypeptide that has at least 85% sequence identity to the mature polypeptide sequence of SEQ ID NO: 2; and
iii) a polypeptide encoded by a nucleic acid that has at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1,
wherein the one or more phospholipids are hydrolysed.
US Pat. No. 10,455,839

PRE-PLANT BIOCIDE USES OF AQUEOUS CYANAMIDES

METBRO DISTRIBUTING LP, ...

1. A method for using a pre-plant biocide to prepare a cultivation medium for growing a plant, the method comprising:i) irrigating an unplanted cultivation medium to a greater than 50% water saturation level;
ii) after the irrigating, allowing the irrigated cultivation medium to drain to a saturation level of 50%-25%; and
iii) contacting the cultivation medium with the pre-plant biocide comprising water and hydrogen cyanamide at a concentration of 600-10,000 ppm, thereby uniformly applying the pre-plant biocide, wherein the contacting is performed 30 to 90 days prior to a time of planting the plant;
and wherein:
(a) the applying the pre-plant biocide reduces a number of viable pathogenic nematodes in the root zone of the cultivation medium by at least about 90% to a depth of 4 feet at the time of planting relative to an untreated control cultivation medium;
(b) the applying the pre-plant biocide reduces a number of viable weeds in the cultivation medium by at least about 99% at the time of planting relative to an untreated control cultivation medium; or
(c) the applying the pre-plant biocide reduces a number of viable pathogenic fungal organisms in the cultivation medium by at least about 90% at the time of planting relative to an untreated control cultivation medium.
US Pat. No. 10,456,352

OXIDATION DYEING AGENT WITH SPECIAL HYDROXY-TERMINATED, AMINE-FUNCTIONALIZED SILICONE POLYMERS

1. Cosmetic agent for coloring keratin fibers, comprising in a cosmetically tolerant carriera) at least one chromophoric compound, selected from the group of oxidative dye precursors, partially-oxidative dyes and the mixtures thereof,
b) at least one hydroxy-terminated amine-functionalized silicone polymer of formula (I)
(O1/2H)t[A]a  (I)
where A=(SiO4/2)k(R1SiO3/2)m(R12SiO2/2)p(R13SiO1/2)q(O2/2SiR1—(CH2)x—B—(CH2)y—NH2)s(O1/2SiR1R2—(CH2)x—B—(CH2)y—NH2)r
wherein
the at least one hydroxy-terminated amine-functionalized silicone polymer of formula (I) is terminated at a first end with a hydroxy group and is terminated at a second end with an amine group,
a denotes integers from 1 to 20,000, wherein, if a ?2, the respective values k, m, p, q, s and r in a structural element A can be selected irrespective of previous structural elements A,
R1 and R2 denote, independently of one another, hydrogen, a OH group, a linear or branched C1-C12-alkyl group, a phenyl group or a vinyl group,
B denotes an oxygen atom, a NH group or sulfur,
x and y denote, independently of one another, integers from 1 to about 10,
t denotes integers from 1 to 5, and
the total of k+m+p+q+s+r denotes integers from 3 to about 20,000.
US Pat. No. 10,458,916

RAPID TESTS FOR THE DETECTION OF INHIBITORS OF ENZYMES AND HUMAN EXPOSURE TO THE SAME

ANP Technologies, Inc., ...

1. A system for detecting presence of an inhibitor of an esterase comprising:a) a self-calibrated, modular, handheld device comprising a top piece and a bottom piece, said bottom piece comprising a negative control reaction zone and a test reaction zone for a test sample suspected of comprising an inhibitor of an esterase; each reaction zone comprising a porous matrix consisting essentially of an immobilized substrate of said esterase, each reaction zone positioned below an opening in said top piece when said top piece is assembled on said bottom piece; and said negative control reaction zone and said test reaction zone are separate and exclusive; wherein in a reaction of said substrate and said esterase, a product of said reaction comprises a detectable reporter; and wherein a negative control reaction zone comprising a negative control sample comprises detectable reporter; and
b) separate from said device, two reaction containers, each container comprising a same amount of said esterase, and optionally,
c) separate from said device, a reader that detects said detectable reporter.
US Pat. No. 10,457,896

DRY AND PORTABLE SPOT REMOVAL PRODUCT AND METHOD COMPRISING AN ALUMINUM DIOCTAHEDRAL PHYLLOSILICATE

Spot Stuff, Inc., Minnet...

1. A method of removing a grease or oil based stain from a substrate consisting essentially of applying a dry and portable stain removal formulation comprising a silica and alumina tetrahedral (zeolite) mineral and an aluminum dioctahedral phyllosilicates mineral, said aluminum dioctahedral phyllosilicates mineral being preheated at least for one hour and between 600 and 1,200° F.
US Pat. No. 10,456,870

METHOD FOR PRODUCING A SOLDERED CONNECTION

1. A method for making a firmly-bonded connection of an electronic component to a substrate, comprisinga) providing an electronic component having a first surface to be connected and a substrate having a second surface to be connected;
b) applying a copper paste onto at least one of the surfaces to be connected and drying the layer of copper paste;
c1) applying a solder agent onto the dried layer of copper paste and arranging the electronic component and the substrate such that the first surface of the electronic component to be connected and the second surface of the substrate to be connected contact each other by the two-layer combination of dried copper paste and solder agent;
or
c2) arranging the electronic component and the substrate such that the first surface of the electronic component to be connected and the second surface of the substrate to be connected contact each other by the dried copper paste, and applying a solder agent next to the layer of dried copper paste; and
d) soldering the arrangement produced in c1) or c2) to generate a firmly-bonded connection between the electronic component and the substrate;
wherein step c1) or step c2) directly follows step b) with no intervening step; and
wherein the copper paste contains (i) 66-98% by weight of a first type of particles each comprising a phosphorus fraction of >0 to ?500 wt-ppm and selected from the group consisting of copper particles, copper-rich copper/zinc alloy particles, and copper-rich copper/tin alloy particles, ii) 1-20% by weight of a second type of particles selected from the group consisting of tin particles, tin-rich tin/copper alloy particles, tin-rich tin/silver alloy particles, and tin-rich tin/copper/silver alloy particles, wherein the second type of particles contain no phosphorus, and (iii) 1-20 percent by weight vehicle, wherein the mean particle diameter of metallic particles (i) and (ii) is ?15 ?m.
US Pat. No. 10,461,228

LED PACKAGING MATERIAL AND MANUFACTURING METHOD OF THE SAME

Shenzhen China Star Optoe...

1. A method for manufacturing a light-emitting diode (LED) packaging material, comprising the following steps:mixing graphene with a curing agent at a predetermined ratio to form a first mixed solution including a mixture of graphene and the curing agent;
providing epoxy resin and an accelerating agent with a predetermined ratio, and adding the epoxy resin and the accelerating agent into the first mixed solution of graphene and the curing agent to form a second mixed solution, which comprises the mixture of graphene and the curing agent that is added with epoxy resin and the accelerating agent; and
subjecting the second mixed solution to an ultrasonic process to form a material of a fully-mixed combination of graphene and epoxy resin,
wherein the first mixed solution is formed by mixing graphene and the curing agent before epoxy resin is added in the first mixed solution.
US Pat. No. 10,455,847

CONFECTIONARY PRODUCTS WITH CALCIUM PHOSPHATE

Perfetti Van Melle S.p.A....

1. A method of treating dentinal sensitivity in a subject in need thereof, said method comprising:administering to said subject a confectionary product free from acids and comprising calcium phosphate, wherein said calcium phosphate consists of from 0.7% to 18% by weight of dibasic calcium phosphate and from 0.07% to 3.6% by weight of tribasic calcium phosphate.
US Pat. No. 10,457,899

POLYFUNCTIONAL POLYMERS BASED ON PHOSPHONATE UNITS AND AMINE UNITS

RHODIA OPERATIONS, Paris...

1. A polyfunctional polymer comprising:monomer units u1 bearing phosphonic acid functions —P(?O)(OH)2 in acid form or, totally or partly, in deprotonated form;
monomer units u2 bearing amine functions, wherein the amine functions of the monomer units u2 comprise primary amines —NH2 that are optionally totally or partly protonated in ammonium form NH3+;
optionally, monomer units u3 bearing alcohol functions —OH.
US Pat. No. 10,456,361

RAPIDLY DEGRADING EMBOLIC PARTICLES WITH THERAPEUTIC AGENT RELEASE

Boston Scientific Scimed,...

1. An embolic particle comprising sub-particles dispersed in a matrix that comprises a biodegradable polymer,wherein the sub-particles comprise a therapeutic agent of low solubility,
(a) wherein said sub-particles comprise elongate particles having an aspect ratio ranging from 10:1 to 1000:1 that comprise said therapeutic agent and/or (b) wherein said sub-particles comprise particles that comprise an anti-tumor agent dispersed in oil,
wherein upon administration to a blood vessel, the matrix of the embolic particle biodegrades and the sub-particles remain localized in the blood vessel such that they continue to release therapeutic agent locally in the blood vessel after the matrix has completely degraded, and
wherein said sub-particles comprise said elongate particles having an aspect ratio ranging from 10:1 to 1000:1 that comprise said therapeutic agent.
US Pat. No. 10,456,362

STABILIZED PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING SAME

SAMYANG BIOPHARMACEUTICAL...

1. A method of preparing a pharmaceutical composition, comprising:(a) preparing a solution comprising pemetrexed or a pharmaceutically acceptable salt thereof, and an aqueous solvent in a container;
(b) freezing the solution in the container to produce a frozen product; and
(c) degassing the frozen product under reduced pressure to obtain a degassed and frozen product,
wherein the degassed and frozen product comprises 95 to 100 parts by weight of the solvent per 100 parts by weight of the solvent contained in the solution of step (a), and
the steps of (b) and (c) are performed in a sealed chamber.
US Pat. No. 10,456,874

MANGANESE-CONTAINING, COBALT-BASED HIGH-TEMPERATURE SOLDER ALLOY, POWDER, COMPONENT AND SOLDERING METHOD

SIEMENS AKTIENGESELLSCHAF...

1. A cobalt-based solder alloy comprising:8% by weight—16% by weight of zirconium (Zr);
6% by weight—10% by weight of tantalum (Ta);
0.5% by weight—1.5% by weight of carbon (C),
8% by weight—12% by weight of manganese (Mn);
at least 0.5% by weight of titanium (Ti); and
having no boron (B), no silicon (Si), no germanium (Ge) and no gallium (Ga).
US Pat. No. 10,456,363

MODIFIED CYCLODEXTRIN COATED MAGNETITE NANOPARTICLES FOR TARGETED DELIVERY OF HYDROPHOBIC DRUGS

1. Beta-cyclodextrin-citrate coated magnetic nanoparticles having a size of 3 to 10 nm, wherein the beta-cyclodextrin-citrate coated magnetic nanoparticles are free of Beta-cyclodextrin-citrate gum Arabic modified nanoparticles, andwherein the beta-cyclodextrin-citrate coated magnetic nanoparticles are loaded with a hydrophobic drug.
US Pat. No. 10,457,902

SOLID TABLET UNIT DOSE OVEN CLEANER

Ecolab USA Inc., Saint P...

1. A pressed solid detergent composition comprising:an alkali metal hydroxide alkalinity source;
sodium carbonate in an amount between 40 wt. % and 90 wt. %;
an anhydrous silicate secondary alkalinity source in an amount between 1% and 10% by weight of the composition;
water, wherein the total water of the composition is in an amount between 0.1 wt. % and 4 wt. %;
at least two polycarboxylic acid polymers having different molecular weights wherein the at least two polycarboxylic acid polymers comprise an acrylic acid polymer having a molecular weight from 1,000 g/mol to 100,000 g/mol;
an aminocarboxylic acid; and
a phosphonate in an amount less than 1 wt. %,
wherein the polycarboxylic acid polymers, aminocarboxylic acid and phosphonate comprise up to 35 wt. % of the composition.
US Pat. No. 10,456,364

USE OF PROCALCITONIN (PCT) IN RISK STRATIFICATION AND PROGNOSIS OF PATIENTS WITH A PRIMARY, NON-INFECTIOUS DISEASE

B.R.A.H.M.S. GmbH, Henni...

1. A method comprising administering an antibiotic to a patient:wherein the patient has a primary disease not being an infection;
wherein, before administering of the antibiotic, the patient has had a level of analyte of procalcitonin or fragments thereof of at least 50 amino acids in length determined and the level of analyte of procalcitonin or fragments thereof of at least 50 amino acids in length determined is between 0.02 and 0.1 ng/mL.
US Pat. No. 10,456,366

COMPOSITION AND METHODS FOR TISSUE REGENERATION

Chiou Consulting, Inc., ...

1. A method for reducing gum recession or promoting gum growth in a human in need thereof comprising:administering to the gum of the human in need thereof an effective amount of a topical composition comprising:
a) a gum-growth-promoting agent consisting of from about 10% to about 95% by weight of propylene glycol;
b) a pharmaceutically acceptable medium; and
c) optionally, a cell-growth promoter;
wherein said administering comprises applying the topical composition to the gum area as a uniform layer or injecting topically into various gum areas providing for absorption of a gum receding or gum growth promoting amount of propylene glycol by the gum.
US Pat. No. 10,455,854

NUTRITIONAL COMPOSITIONS CONTAINING STRUCTURED FAT GLOBULES AND USES THEREOF

MEAD JOHNSON NUTRITION CO...

1. A powdered nutritional composition comprising:a carbohydrate source;
a lipid or fat source, wherein the lipid or fat source comprises milk fat globules formed from an enriched lipid fraction derived from bovine milk that has been subjected to a fractionation procedure, further wherein the milk fat globules comprise from about 40 wt. % to about 55 wt. % saturated fatty acids, from about 35 wt. % to about 45 wt. % monounsaturated fatty acids, and from about 1.4 wt. % to about 6 wt. % polyunsaturated fatty acids, based on the total weight of the lipids present in the milk fat globules;
a protein source; and
a preservative.
US Pat. No. 10,456,367

COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS

The Charlotte Mecklenburg...

1. A method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in a subject, comprising administering a therapeutically effective amount of a CDP-ribitol to a subject in need thereof daily for at least 30 days, thereby treating the disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in the subject, wherein the disorder associated with a mutation or loss of function in the FKRP gene is selected from the group consisting of limb-girdle muscular dystrophy (LGMD2I), Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), congenital muscular dystrophy (CMD), and any combination thereof.
US Pat. No. 10,456,368

COMPOSITIONS FOR MITIGATING BRAIN TRAUMA AND METHODS THEREOF

1. A formulation for mitigating brain trauma, comprising:one or more ?-3 fatty acids;
one or more curcuminoids;
trans-resveratrol;
?-glycerylphosphorylcholine (“?-GPC”); and
uridine-5?-monophosphate (“UMP”),
wherein the formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration.
US Pat. No. 10,456,373

AGENT EXHIBITING ANTI-STRESS, ANXIOLYTIC AND ANTI-DEPRESSION ACTIVITY, AND COMPOSITION BASED THEREON

1. A composition useful for treating stress, anxiety or depression in a subject, wherein the following components are present within the composition in the following mass percent ratios: 10-90% lithium ascorbate, 6-50% vitamin B6, and 4-40% vitamin B1.
US Pat. No. 10,457,913

CORNEAL EPITHELIOID CELLS DERIVED FROM SURFACE ECTODERMAL CELLS

Osaka University, Osaka ...

1. An in vitro or ex vivo method for producing a keratin-12 positive human corneal epithelioid cell, comprising:introducing a lentiviral vector comprising nucleic acids encoding PAX6, KLF4, and OCT4 into a human epithelial cell,
wherein expression of the lentiviral vector induces the production of a keratin 12-positive human corneal epithelioid cell.
US Pat. No. 10,457,914

OPTIMIZED METHODS FOR DIFFERENTIATION OF CELLS INTO CELLS WITH HEPATOCYTE AND HEPATOCYTE PROGENITOR PHENOTYPES, CELLS PRODUCED BY THE METHODS, AND METHODS FOR USING THE CELLS

Katholieke Universiteit L...

1. A cell culture composition, comprising isolated expanded human non-embryonic, non-germ multipotent adult progenitor cells in a culture medium comprising about 5 ng/ml to about 500 ng/ml Wnt3a and about 10 ng/ml to about 1,000 ng/ml Activin A, characterized in that the multipotent adult progenitor cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages, wherein the multipotent adult progenitor cells in the composition are expanded in cell culture for 10-40 doublings prior to being combined with Wnt3a and Activin A, and wherein the amounts of Wnt3a and Activin A are effective to induce the multipotent adult progenitor cells to differentiate into progeny cells with a definitive endoderm phenotype.
US Pat. No. 10,457,916

METHOD FOR INDUCING DIFFERENTIATION OF INSULIN-PRODUCING CELLS

Tokyo Institute of Techno...

1. A method for directed differentiation into insulin-producing cells, comprising culturing endodermal cells in the following steps (a) to (d):(a) culturing the endodermal cells in a medium comprising a hedgehog signaling inhibitor and an FGF;
(b) culturing the cells obtained in step (a) in a medium comprising a retinoic acid receptor agonist, a hedgehog signaling inhibitor and noggin;
(c) culturing the cells obtained in step (b) in a medium comprising a TGF-? type I activin receptor-like kinase-4/-5/-7 inhibitor and noggin; and
(d) culturing the cells obtained in step (c) in a medium comprising GLP-1 receptor agonist and nicotinamide to produce insulin-producing cells,
wherein the concentration of the noggin in steps (b) and (c) is at least 200 ng/ml or more.
US Pat. No. 10,456,124

APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE

ACCESS CLOSURE, INC., Sa...

1. A sealant for sealing a puncture through tissue, comprising:a mass of PEG precursors comprising PEG-ester precursors and PEG-amine precursors, the PEG-amine precursors including a free-amine form of PEG-amine precursors and a salt form of PEG-amine precursors;
wherein the sealant is provided such that the free-amine form of PEG-amine precursors are at least partially cross-linked with the PEG-ester precursors, and the salt form of PEG-amine precursors remain in an unreactive state until exposed to an aqueous physiological environment, whereupon the salt form of PEG-amine precursors undergo in-situ cross-linking with the PEG-ester precursors to provide adhesion to tissue adjacent the puncture.
US Pat. No. 10,457,919

FEEDBACK-RESISTANT ACETOHYDROXY ACID SYNTHASE VARIANT AND METHOD FOR PRODUCING L-VALINE USING THE SAME

CJ CHEILJEDANG CORPORATIO...

1. A polynucleotide encoding an acetohydroxy acid synthase variant in which the 137th amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 3, leucine (L), is substituted with an amino acid other than leucine, and thereby releasing the feedback inhibition to L-valine.
US Pat. No. 10,457,924

VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS

DANISCO US INC, Palo Alt...

1. A variant ?-amylase polypeptide derived from a parental ?-amylase polypeptide, comprising at least two combinable mutations at productive amino acid positions; wherein the mutations are at position S452 and R142, wherein the variant has at least 99% amino acid sequence identity with SEQ ID NO: 3.
US Pat. No. 10,456,386

PHARMACEUTICAL COMPOSITION COMPRISING BETAHISTINE

OTOLANUM AG, Zug (CH)

1. A pharmaceutical composition for intranasal delivery to a human patient, comprising a solution or suspension of a therapeutically effective amount of betahistine dihydrochloride, a viscosity enhancing agent, a moisturizing agent, and a buffer, wherein the pH of the pharmaceutical composition is about 4.4 to about 6.4.
US Pat. No. 10,457,925

PROCESS FOR THE PRODUCTION OF CELLULOLYTIC AND/OR HEMICELLULOLYTIC ENZYMES

IFP ENERGIES NOUVELLES, ...

1. A process for the production of cellulolytic and/or hemicellulolytic enzymes by a cellulolytic and/or hemicellulolytic microorganism, comprising(a) growing the microorganism in a culture medium in the presence of a source of carbon;
(b) inducing the production of the enzymes by the microorganism in the presence of an inducing substrate, wherein said inducing substrate is a mixture of cellulosic hydrolysates, lactose and a solution of hemicellulosic hydrolysates, the quantities of each of the constituents of the mixture are defined by the following limits:
50% to 65% by weight of cellulosic hydrolysates;
22% to 24% by weight of lactose; and
15% to 25% by weight of a solution of hemicellulosic hydrolysates;
the sum of these three constituents being equal to 100%, and wherein the microorganism belongs to the species Trichoderma reesei which is deleted for catabolic repression by glucose,
wherein the inducing substrate is supplied in a solution having a concentration of 350 to 600 g/L, and
wherein both the source of carbon and the inducing substrate comprise sugar, and wherein the cellulosic hydrolysates and the solution of hemicellulosic hydrolysates are obtained from a pretreatment of lignocellulosic biomass, and/or the cellulosic hydrolysates are obtained directly from a process for the transformation of lignocellulosic biomass into ethanol.
US Pat. No. 10,456,387

PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

NLS PHARMACEUTICS AG, St...

1. A method for treating an attention deficit hyperactivity disorder (ADHD) in a human patient by at least reducing impulsivity, comprising orally administering to said patient levophacetoperane, or a pharmaceutically acceptable salt thereof, as the sole active ingredient in an amount effective to reduce impulsivity in said patient ranging from about 5 mg to about 20 mg per day.
US Pat. No. 10,456,388

ANTIHISTAMINE FOR USE IN TREATMENT OF BREAST CANCER

Belina Pharma AB, Helsin...

1. A method of treating breast cancer in a patient diagnosed with breast cancer, the method consisting of administering to the patient an effective amount of desloratadine, wherein the breast cancer is selected from the group consisting of positive and negative ER, PR, her2 breast cancer molecular subtypes, and invasive breast carcinomas, and wherein the patient is not diagnosed with a seasonal allergic condition.
US Pat. No. 10,456,390

COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS

Almirall, S.A., Barcelon...

1. A combination comprising (a) a corticosteroid chosen from budesonide, mometasone furoate, fluticasone propionate and fluticasone furoate and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, wherein the dual muscarinic antagonist-?2 adrenergic agonist compound is trans-4-[{3-[5-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-1H-1,2,3-benzotriazol-1-yl]propyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate saccharinate, wherein the combination is in a form for inhalation by a patient, andwherein the combination of the (a) corticosteroid and (b) dual muscarinic antagonist-?2 adrenergic agonist is in a ratio by weight of (b) to (a) in a range chosen from 1:100 to 1000:1.
US Pat. No. 10,457,930

OIL-BASED MATERIAL-PRODUCING METHOD AND OIL-BASED MATERIAL-PRODUCING APPARATUS

MICROWAVE CHEMICAL CO., L...

1. An oil-based material-producing method, comprising:a placing step of adding water as a dispersion medium and oil-based material-producing microorganisms to a reactor to produce an aqueous slurry consisting of the water, the oil-based material-producing microorganisms and a microwave responsive material;
a microwave irradiation step of irradiating the aqueous slurry in the reactor with microwaves, breaking at least part of the cell walls of the oil-based material-producing microorganisms; and
collecting an oil-based material produced by the oil-based material-producing microorganisms after the microwave irradiation step,
wherein, in the microwave irradiation step, when the oil-based material-producing microorganisms are irradiated with microwaves in a presence of the microwave responsive material, the microwave responsive material is either one of a microwave-absorbing material and a microwave-sensitive material,
wherein the microwave responsive material is able to flow,
wherein the microwave responsive material has a shape for collecting electric field of microwaves,
wherein the microwave responsive material is a conductive substance, and
wherein the shape of the microwave responsive material is a grain shape having a surface provided with multiple pointed projections.
US Pat. No. 10,456,396

DRY EYE TREATMENTS

Oyster Point Pharma, Inc....

1. A method of treating dry eye in an individual in need thereof, comprising administering between 5 micrograms and 600 micrograms of varenicline in alternating nostrils of the individual.
US Pat. No. 10,457,936

MASSIVELY PARALLEL CONTIGUITY MAPPING

UNIVERSITY OF WASHINGTON ...

1. A method for capturing contiguity information comprising:(a) producing tagged end fragments of a nucleic acid molecule in situ on a flowcell by:
(i) adding a flowcell compatible end adaptor to each end of a target DNA molecule, wherein each of the end adaptors comprises a first flowcell sequence;
(ii) physically constraining each end of the target DNA molecule at locations on a flowcell by permitting the first flowcell sequences of each end adaptor to hybridize to flowcell surface-bound primers; and
(iii) treating the target DNA molecule physically constrained to the flowcell with at least one transposase loaded with flowcell compatible insertion adaptors resulting in fragmentation of the target DNA molecule and insertion of an insertion adaptor to each resulting fragment end to provide tagged end fragments of the target DNA molecule that remain physically constrained to the flowcell at their respective locations in step (ii), wherein the insertion adaptors comprise a second flowcell sequence;
(b) performing cluster amplification of the tagged end fragments on the flowcell to produce clusters;
(c) sequencing the tagged end fragments; and
(d) capturing contiguity information by associating sequences of the tagged end fragments to provide paired-end reads of the nucleic acid molecule.
US Pat. No. 10,456,404

TARGETING CGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS

Indiana University Resear...

1. A method for preventing the progression of and/or treating a cystic kidney disease in a subject in need thereof, comprising administering an effective amount of at least one phosphodiesterase inhibitor, at least one pharmaceutically effective phosphodiesterase inhibitor prodrug, at least one pharmaceutically active phosphodiesterase inhibitor metabolite, or a combination thereof to the subject, wherein the phosphodiesterase inhibitor and the pharmaceutically active phosphodiesterase inhibitor metabolite individually inhibits at least one phosphodiesterase selected from the group consisting of: phosphodiesterase type 5; phosphodiesterase type 6; and phosphodiesterase type 9, and the pharmaceutically effective phosphodiesterase inhibitor prodrug is convertible to an active inhibitor of at least one phosphodiesterase selected from the group consisting of: phosphodiesterase type 5; phosphodiesterase type 6; and phosphodiesterase type 9.
US Pat. No. 10,457,944

OLIGOMERS

Royal Holloway, Universit...

1. A method of ameliorating Duchenne muscular dystrophy, the method comprising administering an oligomer to a patient, wherein the oligomer comprises at least 25 nucleotides and has a nucleotide sequence that is:a) identical to at least 25 contiguous nucleotides of CXG XXG CCX CCG GXX CXG AAG GXG XXC XXG (SEQ ID NO: 10); or
b) identical to at least 25 contiguous nucleotides of XXG CCX CCG GXX CXG AAG GXG XXC XXG XAC (SEQ ID NO: 12),wherein X=U or T.
US Pat. No. 10,457,946

METHODS FOR OVERCOMING GLUCOCORTICOID RESISTANCE AND FOR DETERMINING GLUCOCORTICOID RESISTANCE POTENTIAL IN CANCER

1. A method of sensitizing a cancer cell to glucocorticoid-induced apoptosis or cell death, wherein said cell is resistant to glucocorticoid-induced apoptosis or cell death and wherein the expression level of CASP1 gene and/or NLRP3 gene in said cell is increased as compared to a corresponding glucocorticoid-sensitive control, comprising contacting the cell with an effective amount of an inhibitor of CASP1.
US Pat. No. 10,457,947

TARGETING OF HUMAN GLUCOCORTICOID RECEPTOR BETA IN CANCER

The University of Toldeo,...

1. A composition comprising a peptide nucleic acid (PNA) consisting of the sequence TGCCATACACAGTAT [SEQ ID NO:1].
US Pat. No. 10,458,461

BEARING SHAFT AND BEARING

NTN CORPORATION, Osaka (...

1. A bearing shaft provided with an outer peripheral surface that includes a raceway surface on which a rolling element rolls,the bearing shaft being made of steel containing carbon of 0.7% by mass or more,
the raceway surface being formed with a nitrogen-enriched layer, and
the absolute value of compressive residual stress in the surface of the nitrogen-enriched layer being 600 MPa or more and 1700 MPa or less.
US Pat. No. 10,458,979

SOLID SUPPORTED ARTIFICIAL CELL MEMBRANE SYSTEM

Agency for Science, Techn...

1. An artificial cell membrane system comprising:(i) at least one supported membrane protein carrier comprising a polymeric vesicle comprising a circumferential membrane comprising amphiphilic block copolymers, wherein at least one protein is integrated, embedded or inserted in the circumferential membrane of amphiphilic block copolymers via in vitro synthesis, wherein the supported membrane protein carrier comprises a mean diameter of less than 500 nm; and
(ii) a free floating polystyrene microsphere (PS-SA) bead or scintillation proximity assay (SPA) bead suspended in a fluid medium, wherein the PS-SA bead or SPA bead comprises a mean diameter of less than 5 ?m,
wherein the at least one supported membrane protein carrier comprises a direct attachment to a surface of the PS-SA bead or SPA bead, wherein the direct attachment comprises a physisorption attachment, a chemisorption attachment, or combinations thereof, and wherein the surface of the PS-SA bead or SPA bead is decorated with the polymeric vesicle.
US Pat. No. 10,457,954

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR INCREASING NITROGEN USE EFFICIENCY, YIELD, GROWTH RATE, VIGOR, BIOMASS, OIL CONTENT, AND/OR ABIOTIC STRESS TOLERANCE

Evogene Ltd., Rehovot (I...

1. A method of increasing harvest index, leaf blade area, plot coverage, and/or rosette area of a plant, comprising:(a) over-expressing within the plant an exogenous polynucleotide comprising a nucleic acid sequence encoding the polypeptide selected from the group consisting of SEQ ID NOs: 656, 3402, 3403, 3404 and 3405, wherein said exogenous polynucleotide is operably linked to a heterologous constitutive promoter, and
(b) selecting the plant resulting from step (a), said plant overexpressing said exogenous polynucleotide, under nitrogen-limiting conditions which comprise between 0.75-3 millimolar (m M) nitrogen, for an increased harvest index, leaf blade area, plot coverage, and/or rosette area as compared to a non-transformed plant which is grown under the same growth conditions,
(c) isolating the plant or a regenerable portion of said plant selected according to step (b) having said increased harvest index, leaf blade area, plot coverage, and/or rosette area under said nitrogen-limiting conditions so as to obtain an isolated plant or a regenerable portion of said selected plant, and
(d) planting said isolated plant obtained in step (c) or regenerating a plant from said regenerable portion obtained in step (c) to thereby obtain a plant characterized by said increased harvest index, leaf blade area, plot coverage, and/or rosette area under said nitrogen-limiting conditions as compared to said non-transformed plant which is grown under the same growth conditions,
thereby increasing the harvest index, leaf blade area, plot coverage, and/or rosette area of the plant.
US Pat. No. 10,457,955

PLANT PROMOTER FOR TRANSGENE EXPRESSION

Dow AgroSciences LLC, In...

1. A nucleic acid vector comprising a promoter operably linked to:a) a polylinker sequence; or,
b) a heterologous coding sequence;
wherein said promoter comprises a polynucleotide sequence that has at least 98% sequence identity with SEQ ID NO:1.
US Pat. No. 10,458,981

THREE-STEP ACID DISSOCIATION ENZYME LINKED IMMUNOSORBENT (TADELIS) ASSAY

Hoffmann-La Roche Inc., ...

1. A method for determining in a sample the total amount of a ligand of a ligand-binding protein therapeutic comprising the following steps in the following order:subjecting the sample to an acid treatment,
forming in solution a ternary complex comprising
i) an anti-ligand antibody,
ii) the ligand, and
iii) labelled ligand-binding protein,
by adding first the labelled ligand-binding protein to the sample to form a binary labelled ligand-binding protein-ligand complex, and by adding after the formation of the binary complex the anti-ligand antibody to the sample to form a ternary labelled ligand-binding protein-ligand-anti-ligand antibody complex, and
determining the amount of the ternary complex,andthereby determining the amount of the ligand of the ligand-binding protein.
US Pat. No. 10,457,956

SCN PLANTS AND METHODS FOR MAKING THE SAME

UNIVERSITY OF TENNESSEE R...

1. An elite soybean plant, or a part thereof, comprising an introgression or genetic modification resulting in the elite soybean plant or a part thereof an increased expression of: an miRNA selected from SEQ ID NOs: 12, 25 and 34 and/or the gene of SEQ ID NO: 196, wherein compared to the host soybean plant or a part thereof used to produce the elite soybean plant or a part thereof, the elite soybean plant or a part thereof exhibits an increased resistance to an SCN infection.
US Pat. No. 10,456,418

PREPARATION OF PHARMACEUTICAL DOSAGE FORMS CONTAINING IRON (III) SALTS

Navinta, LLC, Ewing, NJ ...

1. A process for directly preparing a liquid pharmaceutical dosage form of ferric pyrophosphate citrate complex composition comprising:mixing a citrate ion source, a pyrophosphate ion source, a sodium ion source, and a ferric ion source in an aqueous based vehicle carrier to form a mixture having an acidic pH;
heating the mixture above room temperature to form a solution;
cooling the heated solution to room temperature or below without isolation of a solid form of ferric pyrophosphate citrate complex; and
adding water to the cooled solution to adjust the ferric ion concentration to about 10 to 250 mM.
US Pat. No. 10,457,957

INSECTICIDAL PROTEINS AND METHODS OF USE

PIONEER HI-BRED IINTERNAT...

1. A polynucleotide comprising a heteroloqous regulatory element operably linked to an isolated nucleic acid molecule encoding a three-domain insecticidal protein comprising a polypeptide sequence having at least 80% sequence identity to SEQ ID NO: 2 and the following protein structure is present in the three-domain insecticidal protein:a) a Domain I, comprising
i) a surface hydrophobic patch comprising
residues corresponding to Phe26, Val48, Pro50, Ile52, Tyr56, Met193, Val202, His205, Tyr206, Phe207, Trp208, Phe209, and Leu210 of SEQ ID NO: 2;
ii) an anti-parallel ?-sheet with four short strands and four ?-helices designated as helix 1, helix 2, helix 3 and helix 4; and
iii) a type 1? ?-turn comprising an amino acid sequence motif as represented by SEQ ID NO: 25;
b) a Domain II; and
c) a Domain III, wherein the surface of Domain II and Domain III comprises a stripe of solvent exposed serine and threonine residues.
US Pat. No. 10,456,419

METHOD FOR TREATING MIGRAINE HEADACHES

1. A method for preventing and treating a headache in a patient, comprising:locating one or more ligaments or muscle insertions that are associated with a cervical spine and a skull of the patient; and
injecting into the determined one or more ligaments or muscle insertions an injectable regenerative solution that includes platelet rich plasma (PRP) or stem cells to repair the one or more ligaments or muscle insertions.
US Pat. No. 10,457,958

LEPIDOPTERAN-ACTIVE CRY1DA1 AMINO ACID SEQUENCE VARIANT PROTEINS

Monsanto Technology LLC, ...

1. An engineered insecticidal protein comprising the amino acid sequence as set forth in SEQ ID NO:42.
US Pat. No. 10,455,908

TIMEPIECE OR PIECE OF JEWELLERY MADE OF GOLD

The Swatch Group Research...

18. A timepiece or piece of jewellery manufactured in a nickel free and cobalt free gold alloy, a weight percent composition of which comprises:between 75% and 77.5% gold,
between 1.35 and 1.45% palladium,
between 20.1 and 23.8% copper, and
the nickel free and cobalt free gold alloy further comprises an element chosen from among iridium, rhenium, and ruthenium, wherein
the nickel free and cobalt free gold alloy includes a resistance to a discoloration that yellows a color of the nickel free and cobalt free gold alloy when the nickel free and cobalt free gold alloy is exposed in at least one of a saline atmosphere, an acid atmosphere, and an atmosphere of sweat, and
the resistance to the discoloration of the nickel free and cobalt free gold alloy is greater than that of a 5N red gold alloy according to ISO standard 8654.
US Pat. No. 10,457,704

SEPARATION PROCESSES FOR PEA PROTEIN

1. A process for the separation of pea protein, said process comprising the steps of:i. providing an aqueous extract of pea protein or a solution of pea protein, said extract or solution of pea protein comprising at least two types of pea proteins;
ii. passing said aqueous extract or solution of pea protein through at least one expanded bed absorption process, wherein said expanded bed absorption process comprises contacting said aqueous extract or solution of pea protein with at least one adsorbent resin which selectively adsorbs at least a first type of pea protein to provide a non-bound protein fraction and a bound protein fraction, said adsorbent resin comprising:
at least one ligand (L1), said at least one ligand (L1) comprising an aromatic or heteroaromatic ring system and one or more acidic groups, or
at least one ligand (L2), said at least one ligand (L2) comprising an alkylamine or alkylarylamine, wherein said alkylamine or alkylarylamine moieties in ligands (L2) comprise an amine substituted with one or more groups selected from:
a. an aryl, benzyl or heteroaryl group;
b. an alkyl group having 4-16 carbon atoms which may be straight, branched or cyclic;
or combinations thereof;
iii. isolating said first type of pea protein from said adsorbent resin, by elution of either the non-bound protein fraction or of the bound protein fraction; and
iv. isolating the second type of pea protein from said adsorbent resin to provide a second pea protein composition which is depleted in said first type of pea protein.
US Pat. No. 10,457,960

METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAS

Regeneron Pharmaceuticals...

1. An in vitro method for making a biallelic modification to a genomic target locus in a genome within a cell, comprising:(I) introducing into a population of cells:
(a) a Cas protein;
(b) a first guide RNA that hybridizes to a first CRISPR RNA recognition sequence within the genomic target locus;
(c) a second guide RNA that hybridizes to a second CRISPR RNA recognition sequence within the genomic target locus; and
(d) a targeting vector comprising a nucleic acid insert flanked by a 5? homology arm that hybridizes to a 5? target sequence within the genomic target locus and a 3? homology arm that hybridizes to a 3? target sequence within the genomic target locus;
wherein the genome comprises a pair of first and second homologous chromosomes comprising the genomic target locus; and
wherein the Cas protein cleaves at least one of the first and second CRISPR RNA recognition sequences to generate at least one double-strand break in each of the first and second homologous chromosomes; and
(II) identifying a cell comprising a modified genomic target locus comprising a deletion and/or an insertion, wherein the identifying comprises performing a quantitative modification-of-allele assay and a retention assay,
wherein the modification-of-allele assay comprises:
(a) a gain-of-allele assay to determine a copy number of a region of the nucleic acid insert in a genomic DNA sample from the cell; and/or
(b) a loss-of-allele assay to determine a copy number in the genomic DNA sample of a region of the genomic target locus targeted for deletion, and
wherein the retention assay determines a copy number in the genomic DNA sample of a region of the 5? target sequence to which the 5? homology arm hybridizes and/or determines a copy number in the genomic DNA sample of a region of the 3? target sequence to which the 3? homology arm hybridizes,
wherein the combination of the modification-of-allele assay and the retention assay distinguishes correct targeted insertion of the nucleic acid insert into the genomic target locus from random transgenic insertions of the nucleic acid insert into genomic locations outside of the genomic target locus and/or distinguishes correct targeted deletions from deletions extending beyond the region of the genomic target locus being targeted for deletion.
US Pat. No. 10,457,705

CARRIER FOR LIGAND IMMOBILIZATION

KANEKA CORPORATION, Osak...

1. A carrier for ligand immobilization, obtained by a process comprising shrinking polysaccharide porous beads such that a shrinkage rate is not less than 10%, and crosslinking the polysaccharide porous beads,wherein
Shrinkage rate (%)=(1?V2/V1)×100
wherein V1 represents a gel volume of the polysaccharide porous beads before the shrinking, and V2 represents a gel volume of the polysaccharide porous beads after the shrinking.
US Pat. No. 10,457,961

CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION

THE BOARD OF TRUSTEES OF ...

1. A system for regulating expression of a target polynucleotide in a lymphocyte, the system comprising:(a) a chimeric receptor polypeptide (receptor) comprising a transmembrane receptor or a fragment thereof, that undergoes a receptor modification including a conformational change or chemical modification upon binding to its ligand, wherein the receptor comprises a cleavage moiety that cleaves a cleavage recognition site; and
(b) a chimeric adaptor polypeptide (adaptor) that binds the receptor in response to the receptor modification, wherein the adaptor comprises a gene modulating polypeptide (GMP) comprising an actuator moiety linked to the cleavage recognition site, and wherein the adaptor does not bind any extracellular ligand,
wherein the target polynucleotide encodes for a protein involved in immune cell regulation, and
wherein the receptor is activatable upon binding of the receptor to the ligand to recruit the adaptor to the receptor, and wherein the receptor releases the actuator moiety from the GMP of the recruited adaptor by action of the cleavage moiety at the cleavage recognition site, to effect regulating expression of the target polynucleotide in the lymphocyte.
US Pat. No. 10,458,987

TUMOR ENERGY METABOLISM PROFILING

1. A diagnostic method for the prediction of tumor prognosis including the likelihood of formation of metastases, relapse occurrence, and/or local recurrence and the provision of a therapy recommendation comprising the steps of(a) incubation of a tumor patient's fresh sample material and a fresh comparative sample material from the patient in a culture medium for a time sufficient to eliminate nutrition, drug and biopsy effects on the energy metabolism in the sample materials:
(b) preparation of a cell homogenate and subcellular fractions from the sample materials of step (a);
(c) determination of enzyme activities of at least one anaerobic key enzyme and at least one aerobic key enzyme of the energy metabolism of the cell homogenate or the subcellular fraction and determination of a quotient for each key enzyme of the enzyme activity determined in the sample material and the enzyme activity determined in the comparative sample material wherein the one or more anaerobic key enzyme is selected from the group consisting of malic enzyme (ME), lactate dehydrogenase (LDH), pyruvate kinase low affinity (PKLA), hexokinase and an acyl-CoA dehydrogenase and wherein the one or more aerobic key enzyme is selected from the group consisting of pyruvate kinase high affinity (PKHA) and cytochrome c oxidase (COX); and
(d) calculation of a ratio of the sum of the anaerobic key enzyme quotients and the sum of the aerobic key enzyme quotients using the quotients determined in step (c) in the sample material and the comparative sample material, wherein a decrease in the ratio of aerobic to anaerobic key enzyme quotients or increase in the ratio of the anaerobic to aerobic key enzyme quotients, when compared to a value for balanced anaerobic and aerobic metabolism, correlates with tumor progression, wherein the patient sample material is selected from the group consisting of tumor tissue slices, tumor cell mass and isolated tumor cells and the comparative sample material is selected from the group consisting of a tumor distant tissue slice and a material which in step (a) is incubated under conditions that up regulate the anaerobic energy metabolism; and
(e) selecting a method of treatment based on the calculated ratio.
US Pat. No. 10,456,423

COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

SMART Surgical, Inc., Bo...

1. A composition for influencing biological growth comprising:a low pH fluid base, wherein the low pH fluid base comprises dextrose;
mononuclear cells obtained from human umbilical cord blood;
VEGF-A, at a concentration within the composition of between 481 picograms per ml and 895 picograms per ml;
PDGF-BB, at a concentration within the composition of between 807 picograms per ml and 1500 picograms per ml;
EGF, at a concentration within the composition of between 715 picograms per ml and 1329 picograms per ml;
SCF, at a concentration within the composition of between 23 picograms per ml and 45 picograms per ml; and
IL-1RA, at a concentration within the composition of between 2215 picograms per ml and 4114 picograms per ml,
wherein the composition is configured for implantation within a human subject.
US Pat. No. 10,456,427

METHOD OF TREATING VIRAL DISEASES AND PROLIFERATIVE DISORDERS

Lobster Unlimited LLC, O...

1. A method of treating a proliferative disorder in a mammal afflicted therewith, said method comprising internally administering an effective amount of lobster hemolymph, lobster hemocyanin, or a derivative of lobster hemocyanin.
US Pat. No. 10,457,455

MEMBER FOR USE IN UNDERSEA APPLICATIONS

Intertape Polymer Corp., ...

1. A member for use in undersea applications comprising a plurality of conduits assembled into a bundle; the conduit being an unbonded, flexible, continuous, spoolable tube; the bundle being wrapped with a pressure-sensitive tape comprising:a backing consisting of a polymeric film; and
a layer of corrosion resistant liquid crystal polymer (LCP) yarn of filaments of polyester of 2-naphthalene-6-carboxylic acid and 4-hydroxy benzoic acid oriented parallel to the length of the tape and adhered directly to the polymeric film by a first pressure sensitive adhesive;
a second pressure sensitive adhesive coated on the first pressure sensitive adhesive and LCP filaments, the second pressure sensitive adhesive defining a functional adhesive layer of the tape, wherein the second pressure sensitive adhesive is the same as the first pressure sensitive adhesive; and
wherein the tape is constructed such that it provides an initial tensile strength of at least 1000 lb/in.
US Pat. No. 10,456,429

USE OF PROBIOTIC MICRO-ORGANISMS AS AN AGENT THAT PROMOTES THE SYNTHESIS OF MELANIN

NESTEC S.A., Vevey (CH)

1. A non-therapeutic cosmetic method which comprises topically administering to a subject at least one probiotic Bifidobacterium longum subsp. longum micro-organism strain registered on Jan. 29, 2001 with CNCM (Paris, France) under the number I-2618, as an agent inducing skin and/or hair pigmentation, for promoting melanin synthesis thereby homogenizing the color of the skin and/or hair of said subject, wherein said Bifidobacterium longum subsp. longum CNCM I-2618 strain is in at least partially inactivated form and is presented in the form of a cell extract or lysate containing cell fragments and metabolites.
US Pat. No. 10,457,712

PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. An expression vector expressing a nucleic acid encoding a peptide consisting of the amino acid sequence of GLIDEVMVL (SEQ ID NO: 22) or FLDANGHFV (SEQ ID NO: 23).
US Pat. No. 10,457,970

EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES

Conagen Inc., Bedford, M...

1. A recombinant cell of the Class Labyrinthulomycetes comprising a genetic modification of a gene that encodes a mannosyl transferase, and further comprising a recombinant nucleic acid encoding a functional glycoprotein or glycopeptide, wherein the cell produces a heterologous glycoprotein or glycopeptide having an N-linked glycan profile that has at least 25% fewer high mannose structures than the N-linked glycan profile from a reference cell that does not comprise the genetic modification in the gene that encodes the mannosyl transferase.
US Pat. No. 10,456,432

ONCOLYTIC HERPES SIMPLEX VIRUS AND THERAPEUTIC USES THEREOF

New York University, New...

1. A variant oncolytic herpes simplex virus (HSV) comprising functionally inactive ICP34.5 encoding genes, wherein at least one of the ICP34.5 encoding genes is rendered functionally inactive by the insertion of an expression cassette comprising:(a) a US11 encoding polynucleotide operably associated with an immediate early (IE) promoter;
(b) a virus-derived heterologous transporter associated with antigen presentation (TAP) inhibitor encoding polynucleotide; and
(c) a CD40 ligand encoding polynucleotide.
US Pat. No. 10,457,719

ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF

The Jackson Laboratory, ...


US Pat. No. 10,456,437

ANTIBACTERIAL WET WIPE FOR SKIN CARE

1. An antibacterial wet wipe for skin care, wherein the wipe is prepared by adding an antibacterial skin care additive solution to a spunlaced non-woven fabric which is used as a base material, wherein the antibacterial skin care additive solution consists of the following components by mass fraction:Tea tree essential oil 5-10%,
Nano silver 2-4%,
Neroli essential oil 3-5%,
Ceramide 1-1.5%,
Glycerin 1-3%,
Water-soluble vitamin E 0-3%,
Emulsifier 0.1-0.5%, and
Deionized water balance,
wherein the nano silver is derived from a nano silver solution with a mass percentage concentration from 500 ppm to 1000 ppm and the average particle size of the nano silver is 1-5 nm, and
wherein the emulsifier is carbomer.
US Pat. No. 10,457,976

PREPARING ANTIBODIES FROM CHO CELL CULTURES FOR CONJUGATION

Seattle Genetics, Inc., ...

1. A method of producing a conjugated antibody, comprising:(a) performing at least one purification step of a purification scheme to obtain at least a partially purified preparation of an antibody from a culture of CHO cells expressing the antibody;
(b) testing the preparation for presence of a CHO cell sulfhydryl oxidizing enzyme;
(c) if the enzyme is detected at a level greater than 0.5 ?g/ml or 33 ppm in the preparation of step (b), repeating steps (a) and (b);
(d) if the enzyme is detected at a level less than 0.5 ?g/ml or 33 ppm in the preparation of step (b), performing the at least one purification step to obtain at least a partially purified preparation of antibody, wherein the at least one purification step of the purification scheme comprises at least one of a step of (i) washing a protein A column with a salt wash at a concentration of 150-500 mM NaCl, (ii) performing depth filtration at 230 L/m2/hr and using at least 15 L/m2 of an equilibration buffer with a pH of 7.5-8 and NaCl concentration of 50-100 mM, (iii) using anion exchange with a quaternary ammonium ion column with a buffer having a pH of 7.5-8 and a conductivity of less than or equal to 11 mS/cm, and (iv) performing phenyl membrane filtration using a buffer having a pH of 6-8 and 0.3-0.4M sodium citrate; and
(e) conjugating the at least partially purified antibody via one or more sulfhydryl groups to a cytotoxic drug to produce the conjugated antibody.
US Pat. No. 10,457,721

ANTI-OSPA ANTIBODIES AND METHODS OF USE

University of Massachuset...

1. An isolated antibody that specifically binds to outer surface protein A (OspA), wherein the antibody comprises the following six CDRs:(a) a CDR-H1 comprising the amino acid sequence of GYSFTSYWIG (SEQ ID NO: 10);
(b) a CDR-H2 comprising the amino acid sequence of FIYPGDSDTRYSPSFQG (SEQ ID NO: 11);
(c) a CDR-H3 comprising the amino acid sequence of ARGILRYFDWFLDY (SEQ ID NO: 4);
(d) a CDR-L1 comprising the amino acid sequence of RASQGISSGSA (SEQ ID NO: 12);
(e) a CDR-L2 comprising the amino acid sequence of DVSSLES (SEQ ID NO: 7); and
(f) a CDR-L3 comprising the amino acid sequence of QQFNSYLLT (SEQ ID NO: 8).
US Pat. No. 10,456,440

ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS

ATRIVA THERAPEUTICS GMBH,...

1. A method for inhibiting a Staphylococcus aureus infection and an influenza virus infection in a cell comprising contacting the cell with an effective amount of a MEK inhibitor, a p38 inhibitor and/or an NF?B inhibitor.
US Pat. No. 10,457,723

IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES

1. An anti-SpA variant IgG antibody comprising:a light chain variable domain and a heavy chain variable domain comprising an antigen recognition region having antigen-specific immune binding to S. aureus protein A (SpA); and
a variant immunoglobulin heavy chain constant region that differs from that of a parent heavy chain constant region by one or more amino acid substitutions, wherein the parent heavy chain constant region includes a CH1 sequence comprising SEQ ID NO:68m, a CH2 sequence comprising SEQ ID NO:76, and a CH3 sequence comprising SEQ ID NO:80;
wherein the one or more amino acid substitutions comprise:
(i) a substitution of H at EU position of 435 with an R (H435R);
a substitution of Y at EU position of 436 with an F (Y436F); or
a substitution of H435R and Y436F; and
(ii) an amino acid substitution that attenuates non-immune binding of S. aureus Fc binding protein, SSL10.
US Pat. No. 10,461,309

METHOD FOR MANUFACTURING ELECTRODE

ASUSTeK COMPUTER INC., T...

1. A method for manufacturing an electrode, comprising:providing a composite material including a carrier layer and a collector layer disposed on the carrier layer, wherein the collector layer includes a first surface and a second surface opposite to each other, and the first surface of the collector layer faces to the carrier layer;
performing a first coating process to coat a first electrode material on the second surface of the collector layer;
performing a first curing process to dry the first electrode material;
removing the carrier layer to expose the first surface of the collector layer after the first electrode material is dried;
performing a second coating process to coat a second electrode material on the first surface of the collector layer, wherein a material of the second electrode material is same with the material of the first electrode material;
performing a second curing process to dry the second electrode material;
providing another carrier layer on a surface of the dried first electrode material far away from the collector layer after the carrier layer is removed and before the second coating process is performed, wherein the another carrier layer is configured on the surface of the collector layer via a release layer; and
removing the another carrier layer and the release layer to expose the surface of the first electrode material after the second electrode material is dried.
US Pat. No. 10,457,724

METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES

MedImmune, LLC, Gaithers...

1. A method for preventing or reducing the severity of S. aureus-associated sepsis in a mammalian subject comprising administering to said subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, wherein the isolated antibody or antigen-binding fragment thereof immunospecifically binds to a Staphylococcus aureus alpha toxin polypeptide and includes:(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 7, 10, 13 or 69;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 8, 11, 14, 17, 70 or 75;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 9, 12, 15, 18, 16, 65, 66, 67, 71, 72, 76 or 78;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or 4;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 2, 5, 73 or 77; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 3, 6, 64, 68 or 74.
US Pat. No. 10,457,980

MULTIPLEX LABELING OF MOLECULES BY SEQUENTIAL HYBRIDIZATION BARCODING

California Institute of T...

1. A method of providing a unique molecular barcode for each unique nucleic acid molecule in a plurality of nucleic acid molecules in a sample, comprising the steps of:(a) performing a first contacting step that involves contacting the sample with a first plurality of detectably labeled oligonucleotides, each of which targets a nucleic acid molecule and is labeled with a detectable moiety, so that the first plurality comprises at least:
(i) a first oligonucleotide targeting a first nucleic acid molecule and labeled with a first detectable moiety; and
(ii) a second oligonucleotide targeting a second nucleic acid molecule and labeled with a second detectable moiety;
(b) imaging the sample after the first contacting step so that interaction by oligonucleotides of the first plurality with their target sequences is detected;
(c) performing a second contacting step that involves contacting the sample with a second plurality of detectably labeled oligonucleotides, which second plurality includes oligonucleotides targeting nucleic acid molecules that are targeted by the first plurality so that the second plurality comprises at least:
(i) a third oligonucleotide, optionally identical in sequence to the first oligonucleotide, targeting the first nucleic acid molecule; and
(ii) a fourth oligonucleotide, optionally identical in sequence to the second oligonucleotide, targeting the second nucleic acid molecule,
wherein the second plurality differs from the first plurality in that at least one of the oligonucleotides present in the second plurality is labeled with a different detectable moiety than the corresponding oligonucleotide targeting the same nucleic acid molecule in the first plurality, so that, in the second plurality:
(iii) the third oligonucleotide is labeled with the first detectable moiety, the second detectable moiety or a third detectable moiety; and
(iv) the fourth oligonucleotide is labeled with the first detectable moiety, the second detectable moiety, the third detectable moiety, or a fourth detectable moiety,
wherein either the third oligonucleotide is labeled with a different detectable moiety than was the first oligonucleotide, or the fourth oligonucleotide is labeled with a different detectable moiety than was the second oligonucleotide, or both;
(d) imaging the sample after the second contacting step so that interaction by oligonucleotides of the second plurality with their target nucleic acid molecules is detected; and
(e) optionally repeating the contacting and imaging steps, each time with a new plurality of detectably labeled oligonucleotides comprising oligonucleotides that target nucleic-acid molecules targeted by the first and second pluralities, wherein each utilized plurality differs from each other utilized plurality, due to at least one difference in detectable moiety labeling of oligonucleotides targeting the same nucleic acid molecule,
wherein steps (a) to (e) produce a unique molecular barcode for each unique nucleic acid molecule in the sample.
US Pat. No. 10,456,443

PEPTIDYL CALCINEURIN INHIBITORS

Ohio State Innovation Fou...

1. A composition, comprising a peptide 7 to 100 amino acids in length comprising the amino acid sequence SEQ ID NO:1, and wherein the composition inhibits calcineurin (CN) —nuclear factor of activated T cell (NFAT) signaling.
US Pat. No. 10,457,727

METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS

ALDERBIO HOLDINGS LLC, L...

1. A rabbit anti-human nerve growth factor (NGF) antibody or antigen binding fragment which comprises the light chain CDR polypeptide sequences of SEQ ID NO: 95; SEQ ID NO: 96; and SEQ ID NO: 97 and the heavy chain CDR polypeptide sequences of SEQ ID NO: 98; SEQ ID NO: 99; and SEQ ID NO: 100.
US Pat. No. 10,456,446

USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE

Korea University Research...

1. A screening method to determine if a medicine can prevent or treat bone disease, comprising:contacting a cell transformed with human small leucine-zipper proteins (sLZIP) and Peroxisome proliferator-activated receptor ?2 (PPAR?2) with a candidate material, wherein either the human sLZIP or PPAR?2 is coupled to a detectable component; and
detecting an increase in formation of the complex of the human sLZIP and PPAR?2 in the cell, whereby said candidate material is determined to be a material capable of preventing or treating bone disease.
US Pat. No. 10,456,447

THERAPEUTIC MODULATION OF SKIN IMMUNE SYSTEM WITH GAL-7

1. A method for treating psoriasis comprising, administering to an individual in need thereof an effective amount of Gal-7, thereby treating the psoriasis.
US Pat. No. 10,456,448

PTD-SMAD7 THERAPEUTICS

The Regents of the Univer...

1. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment comprising amino acids 203-258 of the human Smad7 protein, wherein the Smad7 fragment retains one or more biological activities of the functional full-length Smad7 protein, and with the proviso that the protein molecule lacks at least amino acids 1 to 25 of the human Smad7 protein.
US Pat. No. 10,458,756

FLEXIBLE ADHESIVE BALLISTIC SHIELD

1. A flexible ballistic shield having an adhesive surface for bonding the ballistic shield to a substrate, the ballistic shield comprising at least a base layer of a bonding butyl rubber material and at least a first layer of a ballistic fabric material disposed on an outer-facing surface of the base layer of bonding butyl rubber material, the inner-facing surface of the base layer providing the adhesive surface of the ballistic shield, the bonding butyl rubber material comprising: a butyl rubber selected from the group consisting of polyisobutene, a copolymer of isobutylene and isoprene, and a combination thereof, for attaching the ballistic shield to a substrate of a vehicle or structure, wherein the adhesive, cohesive and elastic qualities of the butyl rubber material penetrate into the threads of the ballistic fabric, and adhere the base surface of the ballistic shield tenaciously to a surface of a substrate.
US Pat. No. 10,456,449

METHODS AND USES FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES

NGM Biopharmaceuticals, I...

1. A method of reducing bile acid synthesis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of(i) a polypeptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:70, and
(ii) at least one additional agent, wherein the additional agent is an anti-CD20 agent, an anti-CD80 agent, an anti-cytokine antibody, an anti-retroviral therapy, an apical sodium bile acid transporter (ASBT) inhibitor, an autoimmune agent, azathioprine, cochicine, a CSCL10 neutralizing antibody, a CXCR3 ligand, cyclosporine, a cytokine anti-inflammatory drug (CSAID), a cytokine, a growth factor, a fibrate, a fish oil, an immune checkpoint inhibitor, or a non-steroidal anti-inflammatory drug (NSAID);
thereby reducing bile acid synthesis in the subject without inducing HGG hepatocellular carcinoma (HCC) formation.
US Pat. No. 10,457,733

AGENTS THAT MODULATE IMMUNE CELL ACTIVATION AND METHODS OF USE THEREOF

Dana-Farber Cancer Instit...

1. A method for upregulating an immune response comprising contacting a cell expressing RGMb with an agent that inhibits the interaction of PD-L2 with RGMb to thereby upregulate the immune response, wherein the agent is a blocking monoclonal antibody that binds RGMb, or an antigen-binding fragment thereof, comprising six CDRs: CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3, wherein the CDR-L1 sequence consists of amino acid residues 44-54 of SEQ ID NO:12, CDR-L2 sequence consists of amino acid residues 70-76 of SEQ ID NO:12, the CDR-L3 sequence consists of amino acid residues 109-116 of SEQ ID NO:12, the CDR-H1 sequence consists of amino acid residues 50-54 of SEQ ID NO:14, the CDR-H2 sequence consists of amino acid residues 69-85 of SEQ ID NO:14, and the CDR-H3 sequence consists of amino acid residues 118-125 of SEQ ID NO:14.
US Pat. No. 10,456,451

PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE


wherein
X3 is any amino acid;
X4 is serine or valine;
X5 is leucine, praline, threonine, or valine; and
X6 is any amino acid residue,
and wherein
(a) Xp is a proteinogenic amino acid(s) or a protease protective organic group and p is any integer from 1 to 4;
(b) said mSDF-1 maintains chemoattractant activity for T cells and is inactivated by matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, and/or cathepsin G at a rate that is at least 50% less than the rate of inactivation of native SDF-1;
(c) said Xp-mSDF-1 maintains chemoattractant activity for T cells, is inactivated by dipeptidyl peptidase IV (DPPIV) at a rate that is at least 50% less than the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2, MMP-9, leukocyte elastase, and/or cathepsin Gat a rate that is at least 50% less than the rate of inactivation of native SDF-1; and
(d) said mSDF-1 or Xp-mSDF-1 peptide does not comprise the amino acid sequence of at least amino acids 1-8 of SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, or SEQ ID NOs: 65-67.
US Pat. No. 10,456,452

COMPOSITIONS AND METHODS FOR IMPROVED ENCAPSULATION OF FUNCTIONAL PROTEINS IN POLYMERIC VESICLES

Poseida Therapeutics, Inc...

1. A composition, comprising:a suspension of a polymersome-encapsulated functional protein, wherein the suspension is prepared by:
thermally blending a quantity of an amphiphilic diblock copolymer with a quantity of polyethylene glycol (PEG), wherein the amphiphilic diblock copolymer comprises poly(ethylene oxide)-block-poly(butadiene) (PEO-b-PBD);
adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, wherein the solution of the functional protein comprises oxymyoglobin or metmyoglobin in phosphate buffered saline (PBS); and
performing at least one dilution step such that polymersomes that are generated are progressively saturated with the functional protein.
US Pat. No. 10,457,991

COMPOSITIONS AND METHODS FOR IDENTIFYING DEPRESSIVE DISORDERS

Northwestern University, ...

1. A panel of biomarkers consisting of an isolated set of 100 or fewer full-length cDNA biomarkers, wherein said isolated set includes DAG1 , CTSB, and TMCC2 full-length cDNA biomarkers.
US Pat. No. 10,457,992

HYPERMETHYLATION BIOMARKERS ASSOCIATED WITH POOR SURVIVAL OUTCOMES FOR HEAD AND NECK SQUAMOUS CELL CANCER

The Johns Hopkins Univers...

1. A method for identifying an increased risk for a poor survival outcome in a subject having head and neck squamous cell cancer comprising:a) obtaining nucleic acid from a test sample from the subject, wherein the test sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, saliva, and a cytological specimen;
b) performing bisulfite modification to the nucleic acid in a);
c) performing quantitative methylation specific PCR (QMSP) on bisulfite modified nucleic acid from b) using PCR primers and probes specific for the promoter region of one or more genes of interest, wherein the one or more genes of interest are selected from the group consisting of PAX1, PAX5, ZIC4, and PLCB1, and the primers and probes are selected from the group consisting of SEQ ID NOS: 4-15;
d) determining the promoter methylation level of the promoter regions of the one or more genes of interest in the nucleic acid from the test sample of the subject;
e) providing a reference non-neoplastic sample, wherein the reference non-neoplastic sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, saliva, and a cytological specimen;
f) comparing the level of promoter methylation of the one or more genes of interest from the test sample of the subject, to the level of promoter methylation of the one or more genes of interest in a reference non-neoplastic sample;
g) identifying an increased risk of poor survival outcome for the subject having head and neck squamous cell cancer when the level of promoter methylation of the one or more genes of interest in the test sample of the subject, is increased relative to the level of promoter methylation of the one or more genes of interest in the reference non-neoplastic test indicating epigenetic silencing of the one or more genes of interest; and
h) adjusting or modifying the planned treatment of the subject as a result of the increased risk of poor survival in the subject having head and neck squamous cell cancer.
US Pat. No. 10,456,454

CNS DELIVERY OF THERAPEUTIC AGENTS

Shire Human Genetic Thera...

1. A formulation for intrathecal administration comprising a lysosomal enzyme at a concentration at or greater than about 5 mg/ml, and a surfactant, wherein the formulation comprises phosphate at a concentration of no greater than 50 mM.
US Pat. No. 10,456,455

TREATMENT OF PSYCHOLOGICAL TRAUMA

Allergan, Inc., Irvine, ...

1. A method of treating at least one symptom of post-traumatic stress disorder in a patient in need thereof, the method comprising the step of administering to the patient a therapeutically effective amount of a composition including a botulinum neurotoxin (BoNT), wherein administration of the composition decreases the at least one symptom of the post-traumatic stress disorder; and wherein the at least one symptom of post-traumatic stress disorder comprises total or partial amnesia of a traumatic event, flashbacks or nightmares wherein the patient re-experiences the traumatic event, avoidance of stimuli associated with the traumatic event, increased arousal including difficulty falling or staying asleep, anger, hyper-vigilance, or combinations thereof.
US Pat. No. 10,456,456

ANTI-IL-6 VACCINE COMPOSITION

PEPTINOV SAS, Paris (FR)...

1. A method for reducing symptoms of an arthritic disease, comprising administering to an individual in need thereof a therapeutically effective amount of at least one cyclized polypeptide with a length equal to 25 amino acids or less, wherein the at least one cyclized polypeptide comprises, or consists of, a sequence selected from the group consisting of SEQ ID NO: 2, 3, 17, 18 and 19, and a variant sequence thereof having at least 90% sequence identity with the sequence of SEQ ID NO: 2, 3, 17, 18 or 19 and elicits a protective anti-human IL-6 immune reaction.
US Pat. No. 10,457,995

SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION

GUARDANT HEALTH, INC., R...

1. A method for detecting copy number variation, comprising:a) attaching a set of molecular barcodes to cell-free nucleic acid molecules obtained or derived from a sample of a subject to produce tagged parent polynucleotides, wherein a plurality of the tagged parent polynucleotides has identical molecular barcodes;
b) amplifying the plurality of the tagged parent polynucleotides, thereby producing progeny polynucleotides;
c) sequencing at least a portion of the progeny polynucleotides to generate sequence reads;
d) mapping the sequence reads derived from the sequencing to a reference sequence to produce mapped reads;
e) grouping the mapped sequence reads into families, wherein, of the families, a family corresponds to sequence reads of one or more progeny polynucleotides amplified from a same tagged parent polynucleotide of the plurality of the tagged parent polynucleotides;
f) quantifying numbers of families mapping to predefined regions of the reference sequence; and
g) determining copy number variation in one or more of the predefined regions from the numbers of families mapping to the predefined regions of the reference sequence.
US Pat. No. 10,456,458

IMMUNOGENIC COMPOSITION OF KILLED LEPTOSPIRA BACTERIA

Intervet Inc., Madison, ...

1. A composition containing an immunogenic cell preparation of killed Leptospira bacteria in an ethylenediaminetetraacetic acid solution; wherein the solution comprises 5 to 50 mmols of ethylenediaminetetraacetic acid per liter; wherein the Leptospira bacteria are selected from the group consisting of Leptospira interrogans serogroup Canicola serovar Portland-Vere, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, and Leptospira kirschneri serogroup Grippotyphosa serovar Dadas.
US Pat. No. 10,457,743

ANTIBODIES RECOGNIZING THE N-TERMINAL PART OF TISSUE FACTOR PATHWAY INHIBITOR CAPABLE OF ELICITING PRO-COAGULANT ACTIVITY

1. An isolated antibody or fragment thereof comprising:said antibody or fragment thereof which specifically binds to an epitope present in amino acid residues 1 to 79 of human TFPI (SEQ ID NO: 2) comprising a heavy chain and a light chain, wherein,
the heavy chain comprises:
a CDR1 sequence corresponding to amino acids 31 to 35 of SEQ ID NO: 6 (NYGVH),
a CDR2 sequence corresponding to amino acids 50 to 65 of SEQ ID NO: 6 (VIWRGGSIDYNAAFMS), and
a CDR3 sequence corresponding to amino acids 98 to 110 of SEQ ID NO: 6 (NSHGNYVGYAMDY); and
the light chain comprises:
a CDR1 sequence corresponding to amino acids 24 to 34 of SEQ ID NO: 7 (KASQSVGPAVA),
a CDR2 sequence corresponding to amino acids 50 to 56 of SEQ ID NO: 7 (SASNRYT), and
a CDR3 sequence corresponding to amino acids 89 to 96 of SEQ ID NO: 7 (QQYTSYPT).
US Pat. No. 10,456,461

CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS

The United States of Amer...

1. A nucleic acid chimera comprising a first nucleotide sequence encoding two structural proteins from a West Nile virus, wherein the structural proteins are premembrane/membrane (prM) and envelope (E), and a second nucleotide sequence encoding capsid (C) and nonstructural proteins from a dengue type 1 virus, dengue type 2 virus, or dengue type 3 virus, wherein the dengue virus is attenuated by a deletion of about 30 nucleotides from the 3? untranslated region of the dengue genome corresponding to the TL2 stem-loop structure and wherein a cleavage site is utilized for joining the dengue virus capsid protein and the West Nile virus prM protein, and wherein the West Nile virus prM protein contains aspartic acid (Asp) at a position 3 amino acids downstream of the cleavage site and contains threonine (Thr) at a position 6 amino acids downstream of the cleavage site wherein the cleavage site corresponds to amino acid position 3 of SEQ ID NO: 3.
US Pat. No. 10,457,744

ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES

Astute Medical, Inc., Sa...


US Pat. No. 10,458,000

PLASMA AND OXYGAS FIRED FURNACE

UMICORE, Brussels (BE)

1. A process for smelting metallurgical charges, comprising:providing an apparatus comprising a bath furnace susceptible to contain a molten charge up to a determined level, characterized in that the furnace is equipped with:
at least one non-transferred plasma torch for the generation of first hot gases;
at least one oxygas burner for the generation of second hot gases gasses; and,
submerged injectors for injecting said first and second hot gases below said determined level;
feeding a metallurgical charge including transition metals and slag formers to the furnace;
smelting the charge using the oxygas burner(s) as a primary enthalpy source, thereby forming an alloy comprising a first part of the transition metals and a slag comprising a second part of the transition metals;
treating the slag in strongly reducing conditions using the plasma torch(es) as primary enthalpy source, thereby forming an alloy enriched in transition metals and a slag depleted in transition metals by transferring said second part of the transition metals from the slag to the alloy; and,
separating the alloy and the depleted slag by tapping.
US Pat. No. 10,457,745

ANTI-COMPLEMENT C1S ANTIBODIES

Bioverativ USA Inc., Wal...

1. A humanized antibody that binds complement C1s protein and comprises:a light chain variable region that comprises a CDR-L1 amino acid sequence set forth in SEQ ID NO: 9, a CDR-L2 amino acid sequence set forth in SEQ ID NO: 10, and a CDR-L3 amino acid sequence set forth in SEQ ID NO: 11;
a heavy chain variable region that comprises a CDR-H1 amino acid sequence set forth in SEQ ID NO: 12, a CDR-H2 amino acid sequence set forth in SEQ ID NO: 13, and a CDR-H3amino acid sequence set forth in SEQ ID NO: 14; and
a human Fc region.
US Pat. No. 10,461,331

LITHIUM BATTERY

NATIONAL CHENG KUNG UNIVE...

1. A lithium battery, comprising:a hollow housing;
an anode disposed in the hollow housing;
a cathode disposed in the hollow housing;
a separator disposed between the anode and the cathode;
a liquid electrolyte filled between the anode and the separator and filled between the cathode and the separator, wherein the liquid electrolyte comprises a lithium ion composition; and
a plurality of graphene oxide quantum dots, wherein the graphene oxide quantum dots have an average particle size between 2 nm and 9 nm, wherein the liquid electrolyte or the separator comprises the graphene oxide quantum dots.
US Pat. No. 10,457,746

COMPOUNDS BINDING TO JMJD6 WITH ANTIFIBROTIC ACTIVITY

1. A monoclonal antibody or a fragment thereof,wherein the monoclonal antibody or a fragment thereof binds to JMJD6,
wherein the monoclonal antibody or a fragment thereof comprises a light chain variable region and a heavy chain variable region,
wherein the light chain variable region comprises the following CDRs: QSILYSSNHKN (SEQ ID NO:42), WASTRESGVP (SEQ ID NO:43), and HQYLSS (SEQ ID NO:44); and
wherein the heavy chain variable region comprises the following CDRs: GFSLSSYG (SEQ ID NO:45), IWRSGNT (SEQ ID NO:46), and AKNFRYDVGSWFAY (SEQ ID NO:47).
US Pat. No. 10,458,002

GREY GOLD ALLOY

1. A grey gold alloy, which is nickel-free, cobalt-free, iron-free, silver-free, zirconium-free, niobium-free, chromium-free, indium-free, gallium-free and manganese-free, comprising, expressed in weight percent, the following elements:75.0 to 76.5% of Au,
15 to 23% of Pd,
1 to 7% of Cu,
0 to 5% of at least one of the alloying elements Ir, Ru, B and Re,
the respective percentages of all the elements of the alloy adding up to 100%.
US Pat. No. 10,457,747

METHOD FOR OBTAINING HIGH-YIELD, STABLE EXPRESSION CELL CLONES AND ANTIBODY MOLECULES OBTAINED THEREBY

BIOTECH PHARMACEUTICAL CO...

1. A method for obtaining stable producer cell clones from myeloma cell lines in protein-free medium producing recombinant antibodies for industrial purposes that comprise three stages:I. placing the myeloma cell lines into a protein-free, lipid-enriched-supplement medium and performing a stepwise reduction of the lipid-enriched supplement until the lipid-enriched supplement is removed,
wherein the stepwise reduction comprises the lipid-enriched-supplement first being in a concentration of about +3.5 g/L until Xv reaches a constant value, then the lipid-enriched-supplement being in a concentration of about +1 g/L until Xv reaches a constant value,
II. and then growing the cell lines, wherein the cell density is about 1.5 1.8×106 cells/ml, thereby producing myeloma cell lines adapted to protein-free medium,
III. placing the myeloma cell lines adapted to protein-free medium into a perfusion fermentation system, wherein the cell density is about 5-10×106 cells/ml, and
IV. selecting stable producer cell clones from cell lines at the end of fermentation of stage II.
US Pat. No. 10,457,748

SINGLE LINKER FABFV ANTIBODIES AND METHODS OF PRODUCING SAME

UCB BIOPHARMA SPRL, Brus...

1. A pharmaceutical composition comprising a purified monomeric form of a multi-specific antibody molecule and at least one excipient, said multi-specific antibody molecule consisting of three polypeptides,a) a polypeptide chain of formula (I):
(Vxx)nVx-Cx-X-V1,
b) a polypeptide chain of formula (II):
(Vyy)nVy-Cy, and
c) a polypeptide of formula (III):
V2,
wherein
Vx represents a variable domain,
Vxx represents a variable domain,
Cx represents a constant region consisting of CH1,
X represents a linker,
V1 represents a variable domain,
Vy represents a variable domain,
Vyy represents a variable domain,
Cy represents a constant region selected from a Ckappa or Clambda sequence,
V2 represents a variable domain,
n independently represents 0 or 1,
wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired, the variable domains Vx and Vy are paired to form a binding domain, the variable domains V1 and V2 are paired to form a binding domain, and a disulphide bond is present between V1 and V2, and wherein at least 90 percent of the antibody molecules in the composition are in monomeric form;
wherein the variable domain pair V1/V2 are linked by a disulfide bond between two engineered cysteine residues, one in V1 and one in V2; and
wherein the position of the pair of engineered cysteine residues is selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43 and VH106 and VL57.
US Pat. No. 10,459,290

OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE

FUJIFILM Corporation, To...

1. An optical film containing a cellulose acylate film wherein:the cellulose acylate film contains a cellulose acylate and an aromatic ester oligomer having a repeating unit derived from a dicarboxylic acid and a repeating unit derived from a diol,
the cellulose acylate film has a thickness of from 15 to 35 ?m,
the repeating unit derived from a dicarboxylic acid has a ratio m/n of from 0/10 to 3/7,
wherein m represents a molar proportion of a repeating unit derived from an aliphatic dicarboxylic acid, and n represents a molar proportion of a repeating unit derived from an aromatic dicarboxylic acid, and
the cellulose acylate film satisfies the following expression (1):
|Rth(590)|?50 nm  (1)
wherein Rth(590) represents a retardation in a thickness direction at a wavelength of 590 nm,
wherein a proportion of a repeating unit derived from ortho-phthalic acid in the repeating unit derived from the dicarboxylic acid contained in the aromatic ester oligomer is 70% by mol or more, and
wherein the Knoop hardness of the optical film is 240 or more N/mm2.
US Pat. No. 10,456,470

DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA

Genentech, Inc., South S...

1. A method of treating a patient having a proneural subtype glioblastoma who is likely to respond to treatment with an anti-VEGF antibody, the method comprising:(a) detecting expression of at least one of the genes set forth in Table 1, 2, or 3 in a biological sample obtained from the patient prior to administration of the anti-VEGF antibody to the patient;
(b) comparing the expression level of the at least one gene to a reference expression level of the at least one gene, wherein a change in the level of expression of the at least one gene in the patient sample relative to the reference expression level identifies the patient as one who has a glioblastoma of the proneural subtype and is likely to respond to treatment with the anti-VEGF antibody; and
(c) administering an effective amount of the anti-VEGF antibody to the patient identified as likely to respond to treatment with the anti-VEGF antibody.
US Pat. No. 10,458,009

FREE-MACHINING WROUGHT ALUMINIUM ALLOY PRODUCT AND MANUFACTURING PROCESS THEREOF

CONSTELLIUM EXTRUSIONS DE...

1. A wrought aluminium alloy product having the following chemical composition, expressed in weight % (wt. %):1.3%?Si?12%,
1.35%?Fe?1.8%wherein the total Fe+Si content is higher than 3.4%;0.15%?Cu?1%;
0.6%?Mg?3%;
optionally, one or more of the following elements:
Mn?1%;
Cr?0.25%;
Ni?3%;
Zn?1%;
Ti?0.1%;
Bi?0.7%;
In?0.7%;
Sn?0.7%
other elements <0.05% each and 0.15% in total;wherein the total Fe+Mn content is lower than 1.9 wt %and the balance aluminium,and wherein ultimate tensile strength of the wrought aluminum alloy product is higher than 400 Mpa.
US Pat. No. 10,456,475

CELL PENETRATING PROTEIN ADAPTOR MOLECULES AND THEIR APPLICATION IN RESEARCH AND MEDICINE

Kennsaw State University ...

1. A biological complex for translocating a cargo into a cell, the complex comprisinga. a cell penetrating peptide (CPP) fused to an adaptor by a covalent linkage, and
b. the cargo, the cargo containing an adaptor binding molecule;
wherein the adaptor binding molecule reversibly binds to the adaptor;
wherein the adaptor is calmodulin and the adaptor binding molecule is a calmodulin binding peptide; and
wherein the CPP is selected from the group consisting of TAT, Penetratin, Transportan, Dat, VP-22, MPG, Pep-1, MAP, SAP, PPTG1, oligoarginine, hCT (9-32), SynB, and Pvec.
US Pat. No. 10,456,480

TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES

Mayo Foundation for Medic...

1. A method for reducing elevated intraocular pressure, said method comprising administering a viral vector to an eye of a mammal under conditions effective to reduce intraocular pressure of said eye, wherein said viral vector comprises a nucleic acid encoding a cyclooxygenase-2 polypeptide.
US Pat. No. 10,457,766

LONG-CHAIN BRANCHED POLYPROPYLENE FOR FILM APPLICATION

BOREALIS AG, Vienna (AT)...

1. A process for producing a long-chain branched propylene homopolymer or copolymer (b-PP), wherein the process comprises:producing a propylene homopolymer or copolymer having a comonomer content in the copolymer selected from ethylene, C4-C20-alpha olefin and any combination thereof, with a comonomer content in the range of 0.1 to 7.0 wt %, in a polymerization process in the presence of a catalyst system comprising:
(a) a Ziegler-Natta based catalyst with a transition metal of Group 4 to 6 (TM), the catalyst containing an internal donor,
(b) optionally a co-catalyst (Co),
(c) optionally an external donor (ED) and wherein if present, the co-catalyst (Co) to external donor (ED) molar ratio [Co/ED] is in the range of 3.0 to 45.0 mol/mol and wherein the co-catalyst (Co) to transition metal of Group 4 to 6 (TM) molar ratio [Co/TM] is in the range of 40.0 to 500 mol/mol;
wherein the resulting propylene homopolymer or copolymer powder has:
(a) a porosity of more than 8.0%,
(b) a median particle size d50 in the range of 150 to 1500 ?m, and
(c) a top-cut particle size d95 in the range of 500 to 400 ?m,
wherein the internal donor comprised in the Ziegler-Natta catalyst (a) is a non-phthalic compound; and
mixing said propylene homopolymer or copolymer with a thermally decomposing free radical-forming agent and optionally with at least one functionally unsaturated compound at a temperature of 20 to 100° C. for at least 2 minutes to form a pre-mixed material and melt mixing the premixed material in a melt mixing device at a barrel temperature in the range of 180 to 300° C. to obtain said long-chain branched propylene homopolymer or copolymer (b-PP), wherein the long-chain branched propylene homopolymer or copolymer (b-PP) has:
(a) a comonomer in the copolymer selected from ethylene, C4-C20-alpha olefin and any combination thereof and a comonomer content in the range of 0.1 to 7.0 wt %,
(b) the melt flow rate MFR2 (230° C.) of the b-PP is in the range of 6.5 to 25.0 g/10 min as measured according to ISO 1133,
(c) the F30 melt strength of the b-PP is in the range of 5.0 to 12.0 cN wherein the F30 melt strength of the b-PP is measured according to ISO 16790:2005,
(d) the xylene hot insoluble (XHU) fraction of the b-PP is less than 0.08 wt % as measured according to EN 579, and
(e) the b-PP is free of phthalic compound.
US Pat. No. 10,457,771

BIOBASED HYDROXYL OR CARBOXYL POLYESTER RESINS

Arkema France, Colombes ...

1. A polyester resin having a linear or branched structure and free of unsaturated fatty acids, which is hydroxylated or carboxylated, optionally hydroxylated and carboxylated, which is derived from:a) an acid component a) comprising:
a1) at least one C4 to C6 polycarboxylic acid or anhydride,
a2) at least one C8 to C54 polycarboxylic acid or anhydride, wherein said polycarboxylic acid a2) is biobased and chosen from the group consisting of azelaic acid (C9), sebacic acid (C10), undecanedioic acid, dodecanedioic acid, and respectively C36 and C54 fatty acid dimers and trimers,
a3) optionally, at least one C2 to C22 saturated monoacid, which can optionally bear a hydroxyl group,
wherein the a1/a2 molar ratio ranges from 2 to 8,
b) an alcohol component b) comprising:
b1) at least one biobased polyol having a functionality fb1 of at least 2, bearing a 1,4:3,6-dianhydrohexitol unit,
and at least one of the following two polyols b2) and b3):
b2) at least one polyol different than b1) and having a functionality fb2 of at least 2, wherein said polyol b2) is biobased and is chosen from the group consisting of 1,3-propylenediol, 1,2-propylenediol, 1,4-butanediol, and diols derived from saturated fatty acids,
b3) at least one polyol different than b1) and than b2) having a functionality fb3 of at least 3;
wherein at least 50% by weight of said resin is biobased, the polyester resin having a carboxyl functionality corresponding to an acid number of less than 20 mg KOH/g and an OH functionality corresponding to an OH number ranging from 10 to 200 mg KOH/g.
US Pat. No. 10,456,746

SELECTIVE CATALYTIC REDUCTION FILTER FOR REDUCING NITROUS OXIDE FORMATION AND METHODS OF USING THE SAME

GM GLOBAL TECHNOLOGY OPER...

1. A selective catalytic reduction filter (SCRF) comprising:a wall-flow substrate defining inlet channels for receiving exhaust gas and outlet channels through which the exhaust gas exits, wherein the inlet channels and the outlet channels are connected to one another through porous walls of the inlet and outlet channels;
a first selective catalytic reduction (SCR) catalyst zone present in the inlet channels, wherein the first SCR catalyst zone has a first SCR catalyst loading and comprises a first SCR catalyst coating comprising an iron-exchanged zeolite; and
a second SCR catalyst zone present in the outlet channels, wherein the second SCR catalyst zone has a second SCR catalyst loading and comprises a second SCR catalyst coating comprising a copper-exchanged zeolite;
wherein the combined first SCR catalyst loading and the second SCR catalyst loading is less than or equal to about 200 g/l.
US Pat. No. 10,458,031

FE—NI ALLOY METAL FOIL HAVING EXCELLENT HEAT RESILIENCE AND METHOD FOR MANUFACTURING SAME

POSCO, Pohang-si, Gyeong...

1. An Fe—Ni alloy metal foil having excellent heat resilience, manufactured using an EF method and having a thickness of 100 ?m or less (excluding 0 ?m), the Fe—Ni alloy metal foil comprising, by wt %, Ni: 34% to 46%, Fe as a residual component of the Fe—Ni alloy metal foil, and inevitable impurities,wherein microstructure of the Fe—Ni alloy metal foil has a face-centered cubic (FCC) and body-centered cubic (BCC) structure, and an area percentage of BCC is in a range of 5% to 20%,
wherein the Fe—Ni alloy metal foil has a heat resilience rate expressed using Formula 1, below, of 30 ppm or lower,
Heat resilience rate=(L?L0)/L0,  [Formula 1]
where L0 is a length of a metal foil before heat treatment (at a surface temperature of 30° C.), and L is a length of a metal foil after heat treatment and refers to the length of the metal foil when a surface temperature of an alloy having a surface temperature of 30° C. is increased to 300° C. at a rate of 5° C./min, maintained at a surface temperature of 300° C. for 5 minutes, and decreased to 30° C. at a rate of 5° C./min.
US Pat. No. 10,457,777

CARBAMYLATION COMPOSITIONS OF MONOVALENT METAL CONTAINING CATALYSTS, POLYOLS AND UREA COMPOUNDS AND CARBAMYLATION PROCESSES USING THE SAME

Dow Global Technologies L...

1. A carbamylation composition comprising from 0.1 to 1 wt. %, based on total solids, of one or more catalyst (i) which is a monovalent or alkali metal compound containing an anionic group, one or more urea compounds and one or more polymeric polyols, wherein the ratio of moles of the urea compound to molar equivalents of hydroxyl groups in the one or more polyol (urea:OH) ranges from 0.3:1 to 2.5:1 wherein the catalyst (i) is chosen from alkali metal acetylacetonates, 2,2,6,6-tetramethyl-3,5-heptanedionato cesium, alkali metal esters from alkanoic acids, alkali metal esters from sulfonic acids, alkali metal esters from halogenated sulfonic acids, copper (I) sulfonic metal esters, copper (I) halogenated sulfonic acid metal esters, silver (I) sulfonic acid metal esters, silver (I) halogenated sulfonic acid metal esters, cesium trifluoroacetate, and mixtures thereof.
US Pat. No. 10,460,851

SILVER-TELLURIUM-COATED GLASS POWDER, PRODUCTION METHOD FOR SILVER-TELLURIUM-COATED GLASS POWDER, CONDUCTIVE PASTE, AND PRODUCTION METHOD FOR CONDUCTIVE PASTE

DOWA Electronics Material...

1. A silver-tellurium-coated glass powder comprising:a tellurium-based glass powder containing tellurium in an amount of 20% by mass or more; and
a coating layer on a surface of the tellurium-based glass powder, the coating layer containing silver and tellurium as a main component.
US Pat. No. 10,456,499

ADHESIVE ARTICLES FOR MEDICAL APPLICATIONS

3M INNOVATIVE PROPERTIES ...

1. An adhesive article comprising:a siloxane-based pressure sensitive adhesive layer; and
a breathable conformable backing comprising a first surface and a second surface, wherein the siloxane-based pressure sensitive adhesive layer is disposed on the first surface of the breathable conformable backing, and wherein the second surface of the breathable conformable backing comprises a treated surface, wherein the treated surface is not a pressure sensitive adhesive and wherein the treated surface provides increased adhesion to non-siloxane-based pressure sensitive adhesives when compared to the adhesion to the same backing without the treated surface, and wherein the treated surface of the breathable conformable backing is prepared by a coating, and wherein when the surface treatment includes a single coating, the coating covers the entire second surface of the backing and is a low adhesion backsize (LAB) such that in a roll of the adhesive article where the adhesive layer contacts the treated second surface of the backing, the adhesion of the siloxane-based pressure sensitive adhesive to the treated second surface is sufficiently low that the roll may be unwound.
US Pat. No. 10,456,501

COMPOSITIONS AND METHODS FOR CARDIAC THERAPY

Ventrix, Inc., San Diego...

1. A composition comprising digested, decellularized extracellular matrix derived from tissue, the extracellular matrix having a pore size of about 30 to 40 microns, wherein the composition is injectable through a catheter with an inner diameter of 25G or smaller, and wherein the extracellular matrix comprises glycosaminoglycan in a concentration of between about 60 to 120 ?g per mL of the extracellular matrix.
US Pat. No. 10,456,502

BONE VOID FILLER PREPARATION SYSTEM

Fortus Medical, Inc., Mi...

1. A method of recovering connective tissue progenitor cells from bone marrow aspirate comprising:providing a bone void filler preparation container having an inlet port and an outlet port;
placing a bone graft matrix having a particle size of between about 1,000 ?m and 2,000 ?m in the bone void filler preparation container;
depleting a concentration of a red blood cells in a bone marrow aspirate to form red blood cell depleted tissue;
passing the red blood cell depleted tissue through the bone void filler preparation container;
and
retaining the connective tissue progenitor cells in the red blood depleted tissue in the bone void filler preparation container, wherein a selection ratio is a ratio of a connective tissue progenitor cell loading efficiency to a total nucleated cell loading efficiency where the connective tissue progenitor cell loading efficiency is a ratio of the progenitor cells retained in the bone void filler preparation container to the progenitor cells loaded in the bone void filler preparation container and the total nucleated cell loading efficiency is a ratio of a total number of nucleated cells retained in the bone void filler preparation container to the total number of nucleated cells loaded in the bone void filler preparation container where the selection ration is greater than about 3.